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1. INTRODUCTION 
 
                       
Cardiovascular Diseases (CVD) are the most prevalent cause of death and 
disability in both developed as well as developing countries.1 South Asians around the 
globe have the highest rates of Coronary Artery Disease (CAD).2 According to National 
Commission on Macroeconomics and Health (NCMH), a Government of India 
undertaking, there would be around 62 million patients with CAD by 2015 in India.3 Thus 
the prevalence of CVD is expected to increase in the next decade, predominantly because 
of increasingly sedentary lifestyles and an attendant increase in the prevalence of obesity 
and diabetes mellitus. 
 
CAD is usually due to atherosclerosis of large and medium sized arteries.  
Atherosclerosis is a multifocal, smoldering, immunoinflammatory disease of the artery 
undergoing gradual lipid deposition and intima thickening, resulting in elasticity decrease, 
lumen occlusion and reduced blood flow 4, 5. Such a diffuse process may start early in 
childhood and progresses asymptomatically through adult life as a relatively benign 
disease that is rarely fatal by itself.6 The most devastating complications of atherosclerosis, 
i.e. life-threatening clinical events, such as acute coronary syndrome and stroke, are 
provoked by arterial occlusion precipitated by atherosclerotic plaque erosion or disruption 
with superimposed thrombosis. This process is defined as atherothrombosis.6, 7 The most 
common complications of this pathologic condition are ischemic heart disease, heart 
attacks, cerebral strokes (CVA), and brain degeneration.  
 
Development of atherosclerosis involves multiple metabolic and cellular 
processes.8, 9 It is generally considered a chronic inflammatory disease developing as a 
response to endothelial activation and dysfunction that leads to progressive 
vasoconstrictive impact and proinflammatory, prothrombotic, procoagulative and 
proliferative processes in the vessel wall, i.e. initiates the sequence of successive reactions 
prompting composition of atherosclerotic plaque.10 
 
Patients with central obesity, insulin resistance, hypertension, and type 2 diabetes 
mellitus have a unique dyslipoproteinaemia characterized by hypertriglyceridemia, 
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elevated levels of small dense low-density lipoprotein (LDL) cholesterol, and low levels of 
HDL cholesterol. Thus lipoproteins are the major risk factors in cardiovascular disease. 
 
Correlations between coronary artery disease and the properties, compositions, and 
plasma concentrations of various lipid and lipoproteins have revealed mechanisms that 
ultimately aid diagnosis and provided new targets for pharmacological management of 
dyslipidemia and atherosclerosis. 
 
Blood lipid assessment forms an essential step in the assessment of almost every 
cardiac patient, whether middle aged or elderly. Risk factor assessment is integral to the 
cardiovascular management of all patients. Regrettably, large numbers of drug-eligible 
patients who may benefit from statins and other lipid lowering drugs are still not receiving 
them.11 
 
The main focus in treating lipid disorders is on reducing LDL-cholesterol 
concentrations. Also, lipid-related independent risk factors, such as triglyceride, HDL 
cholesterol, and lipoprotein (a) levels should be used clinically to assess the cardiovascular 
risk. 
 
1.1. DYSLIPIDEMIA 
 
Dyslipidemia is the term given to abnormalities in blood levels. Dyslipidemia is a 
disorder of lipoprotein metabolism, including lipoprotein overproduction and deficiency.12 
They may manifest as one or more of the following: 
 
¾ Elevated Total Cholesterol 
¾ Elevated low Density Lipoprotein 
¾ Elevated Triglycerides  
¾ Decreased High Density Lipoprotein Cholesterol (HDL). 
 
Disorders of lipoprotein metabolism, together with the prevalence of high-fat diets, 
obesity, and physical inactivity, have resulted in an epidemic of atherosclerotic disease in 
the developing countries. The interaction of common genetic and acquired disorders of 
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lipoproteins with these adverse environmental factors predisposes to premature 
atherosclerosis. 
 
The recognition that low levels of High Density Lipoprotein (HDL) and the 
presence of small dense low Density Lipoprotein (LDL) particles are clinically important 
in the development of CAD has led to the use of term dyslipidemia to describe a range of 
disorders that include both abnormally high and low lipoprotein levels as well as 
abnormalities in the composition of these particles. Thus Dyslipidemia is clinically 
important to atherogenesis. 
 
 
1.2. CLASSIFICATIONS OF DYSLIPIDEMIAS 
 
        Dyslipidemia can be classified in two ways: 
 
 
¾ First classification depends on measurement of the concentrations of plasma 
triglycerides, Total cholesterol and HDL cholesterol.13 
 
 
Table No: 1 
 
 
Cholesterol Disorders 
 
Cholesterol level elevated and exceeds 
triglyceride concentration 
 
Triglyceride Disorders 
 
Triglyceride level elevated and exceeds 
Cholesterol concentration 
 
HDL cholesterol concentration reduced
 
 
<35 mg/dl 
 
 
Hypercholesterolemia is associated with an increased concentration of one or more 
of the cholesterol-carrying lipoproteins (LDL, VLDL, HDL), which may occur because of 
a higher concentration of cholesterol in each particle, an increased number of particles, or 
a combination of both. Both VLDL and LDL particles contain one apolipoprotein B-100 
molecule and, therefore, an elevation of the apolipoprotein B concentration reflects an 
increased number of cholesterol-containing particles, which is associated with 
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hypercholesterolemia. The most common cause of hypercholesterolemia is an elevation in 
LDL cholesterol.14 
 
The most studied forms of dyslipidemia are familial hypercholesterolemia. These 
patients have a defective gene from one or both parents for the B-E/LDL receptor, 
significantly reducing their ability to clear LDL from the blood. Homozygous familial 
hypercholesterolemia can result in four to six times the normal concentrations of 
cholesterol and significant atherosclerotic disease, detected during the teenage years. 
Heterozygous familial hypercholesterolemia can cause two to four times the normal 
concentrations of cholesterol with premature atherosclerotic disease.14, 15 
 
Hypertriglyceridemia occurs in patients with high concentrations of VLDL or 
chylomicron particles. Most cases are mild and are primarily caused by increased VLDL 
secretion by the liver in patients who consume an excessive amount of calories or alcohol 
(diet-induced hypertriglyceridemia). VLDL secretion can also increase secondary to 
diabetes, obesity, or other medical problems (secondary hypertriglyceridemia). Primary 
hypertriglyceridemia occurs because of an overproduction of triglycerides and VLDL 
particles and is often associated with other medical conditions including diabetes and 
obesity. Hypertriglyceridemia is not usually an isolated condition. It tends to be associated 
with patients who have low concentrations of HDL cholesterol and elevated levels of LDL 
particles, posing the risk for atherogenesis. Mixed hyperlipidemias are the most common 
forms of dyslipidemia where patients may have elevations in both triglyceride and 
cholesterol levels. 
 
Patients with reduced HDL cholesterol concentrations often have normal total 
cholesterol concentrations and normal or only slightly elevated LDL cholesterol levels. As 
a consequence, their LDL levels may not be elevated enough to meet the National 
Cholesterol Program guidelines for drug therapy despite the well-accepted fact that these 
patients are at increased risk of developing coronary heart disease.16 
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¾ Second classification is Fredrickson classification which is based on the pattern of 
lipoproteins on electrophoresis or ultracentrifugation. There are two major ways in 
which dyslipidemia are classified.17 
 
      a) Phenotype 
Table No: 2 
Lipoprotein Patterns (Fredrickson Phenotypes) 
Phenotype Elevated Lipoprotein(s) Elevated Lipids 
I Chylomicrons TGs 
IIa LDL Cholesterol 
IIb LDL and VLDL TGs and cholesterol 
III VLDL and chylomicron 
remnants
TGs and cholesterol 
IV VLDL TGs 
V Chylomicrons and VLDL TGs and cholesterol 
 
 
 b) Etiology 
 
Primary causes:  
Primary causes are single or multiple gene mutations that result in either 
overproduction or defective clearance of TG and LDL cholesterol, or in underproduction 
or excessive clearance of HDL. 
 
Secondary causes:  
The most important secondary cause in developed countries is a sedentary lifestyle 
with excessive dietary intake of saturated fat, cholesterol, and trans fats. Other common 
secondary causes include diabetes mellitus, alcohol overuse, chronic kidney disease, 
hypothyroidism, primary biliary cirrhosis and other cholestatic liver diseases, and drugs, 
such as thiazides, β-blockers, retinoids, highly active antiretroviral agents, estrogen and 
progestins, and glucocorticoids. 
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1.3. EPIDEMIOLOGY 
 
Heart disease and stroke are the principal components of cardiovascular disease. 
Heart disease and stroke are usually due to atherosclerosis of large and medium sized 
arteries. Hypercholesterolemia is the most important factor in the pathogenesis of 
atherosclerosis.18, 19 
Hypertension, smoking, diabetes, obesity, physical inactivity, and atherogenic diets 
have all been identified as modifiable risk factors for heart disease. Age, male gender, and 
a family history of premature coronary heart disease (CHD) have been identified as non 
modifiable risk factors.20 
 
The National Cholesterol Education Program Adult Treatment Panel on Detection, 
Evaluation, and Treatment Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (NCEP ATP) published NCEP ATP I, NCEP ATP II, 13 and most 
recently NCEP ATP III.21 The executive summary of NCEP ATP III was published in 
May 2001.22 The full report of NCEP ATP III was published in December 2002. The 
NCEP is coordinated by the National Heart, Lung, and Blood Institute (NHLBI) of the 
National Institute of Health (NIH).21 
HISTORICAL PERSPECTIVE 
Based on Framingham Heart Study results reported in 1961, the concept of risk 
factors for coronary heart disease was clearly established. Hypertension and 
hypercholesterolemia were initially identified as major contributors to cardiovascular 
disease.23 The NCEP guidelines were updated in 1993, and the “Third Report of the NCEP 
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults,” also known as Adult Treatment Panel (ATP III), was issued in 200l. 
 
ASSESSING RISK IN ASIAN INDIANS 
 
The common pattern of dyslipidemia seen in Asia Indians when compared to the 
lipid profile of white Americans is listed in Table.No:324, 25, 26, 27 Asian Indians tend to 
have higher levels of triglycerides, lower HDL levels, and higher levels of Lp (a). 
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Table No: 3 
 
 
 
Total cholesterol levels and LDL levels are correlated with extent and severity of 
CHD in Asian Indians as in whites. But at any given total cholesterol or LDL level, Asian 
Indians have a greater CHD risk than whites.28, 29 Therefore, Asian Indians with 
dyslipidemia should be treated as aggressively as if they had a CHD risk equivalent similar 
to the treatment of patients with diabetes or heart disease. Thus, while a total cholesterol 
level of <200 mg/dL is desirable according to the Framingham model for those with 0 to 1 
risk factor, the goal for the Asian Indian population should be <160 mg/dL. An LDL level 
of <160 mg/dL is appropriate for most Americans with 0 to 1 risk factor, but a level of 
<100 mg/dL is optimal for Asian Indians.30 
 
HDL levels of 60 mg/dL are considered optimal in both whites and Asian Indians. 
HDL levels are considered low when they drop below 40 mg/dL. However, most experts 
consider a level <50mg/dL to be low in women.31 
 
The acceptable “normal” level of triglycerides was decreased from <200 mg/dL in 
the ATP II report to <150 mg/dL in the ATP III classification. Lipoprotein (a) is still 
considered an emerging risk factor in the US population at large, but appears to be a major 
risk factor in Asian Indians.32, 33, 34, 35, 36 A high level of Lp (a) is the most prevalent 
dyslipidemia in patients with premature CHD. Lp (a) levels are governed almost 
exclusively by race, ethnicity, and genetics, unlike other lipids, where the levels are 
influenced by age, gender, diet, and other environmental factors. Although Lp(a) levels 
>30 mg/dL are generally considered the threshold at which high risk of premature CHD 
increases rapidly, levels below 20 mg/dL are considered optimum, particularly in Asian 
Indians.37  
Pattern of Dyslipidemia among Asian Indians Relative to American 
Whites. 
Lipid Relative Serum  Concentration 
TC Similar 
LDL Similar 
Triglycerides Higher 
HDL Lower 
Lp(a) Higher 
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When combined with concomitant elevation of triglycerides, and LDL, and 
decreases in HDL concentrations, the pathophysiological effects of elevated Lp (a) are 
exponentially increased.38 This “deadly lipid quartet,” commonly present in Asian Indians, 
usually results from affluent lifestyles led by immigrants, as well as those living in urban 
areas in India.39 The high rates of CHD in Asian Indians are due to a combination of 
genetic predisposition and lifestyle factors. 
 
PREVENTION OF CHD IN ASIAN INDIANS 
 
The most important aspect of preventing CHD is identifying individuals at high 
risk of developing CHD at an early age. Since Lp (a) is fully expressed in the first year of 
life, tracking Lp (a) from childhood may be a better option than focusing on other 
dyslipidemia that are not expressed until later life.39 This is particularly true of those with 
a family history of premature CHD. 
 
Modification of lifestyle, such as increasing physical activity and decreasing 
consumption of calories particularly saturated fat should begin early in life. Abdominal 
obesity should be avoided. Consumption of all types of tobacco products should be 
eliminated. Appropriate drug therapy should be considered for all lipid abnormalities and 
risk factor abnormalities, which do not respond to lifestyle adjustment.40, 41, 42 
 
1.4. LIPIDS AND LIPOPROTEINS 
 
The French Physician-scientist Michel Macheboeuf is known as the Father of 
plasma lipoproteins.43 Lipids are a chemically diverse group of compounds that are 
poorly soluble in the aqueous environment of the cell. The main ones being cholesterol, 
triglyceride and phospholipids. Lipids are transported in plasma as components of 
lipoprotein complexes. Lipoproteins are spherical complex particles composed of neutral 
lipids, polar lipids and specialized proteins called apolipoproteins (apos). 
 
The lipids are mainly free and esterified cholesterol, triglycerides, and 
phospholipids. The hydrophobic triglyceride and cholesteryl esters (CEs) compose the 
core of the lipoproteins, which is covered by a unilamellar surface that contains mainly the 
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amphipathic (both hydrophobic and hydrophilic) phospholipids and smaller amounts of 
free cholesterol and proteins. 
 
Apolipoproteins are the proteins on the surface of the lipoproteins. They not only 
participate in solubilizing core lipids but also help in the regulation of plasma lipid and 
lipoprotein transport.44 
 
Lipids have important roles in virtually all aspects of life: serving as hormones, 
serving as an energy source, aiding in digestion, acting as structural components in cell 
membrane. In addition, lipid and lipoproteins are intimately involved in the development 
of atherosclerosis, a pathogenic process that is the underlying cause of the common 
cardiovascular disorders of MI, cerebrovascular diseases, PVD.45 
 
CLASSIFICATION OF LIPOPROTEINS 
 
Based on their densities, lipoproteins have been classified into: 46 
 
 Chylomicrons 
 Very Low Density Lipoproteins (VLDL) 
 Intermediate Density Lipoproteins (IDL) 
 Low Density Lipoproteins (LDL) 
 High Density Lipoproteins (HDL) 
 
Table No: 4 
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CHYLOMICRONS 
 
Chylomicrons are synthesized in the absorptive cells in the small intestine and 
transport dietary triglyceride from the small intestine via the lymph into plasma. They are 
the largest lipoprotein and are rich in triglycerides.47 They consist of highest quantity of 
lipids (99%) and lowest concentration of proteins (1%). They contain 90% to 95% of 
triglycerides, 2% to 6% phospholipids, 2% to 4% cholesteryl ester, 1% free cholesterol 
and 1% to 2% apolipoprotein. Apolipoproteins present are apo C and apo B-48 (most 
abundant) along with small amounts of apo E, AI, AII and AIV. They are not found in 12 
to 24 hour fasting specimens. Chylomicrons transport exogenous lipids to liver, adipose, 
cardiac, and skeletal muscle tissue. The capillary beds of these tissues contain high 
concentrations of LPL. LPL hydrolyzes TG in the chylomicrons into free fatty acids that 
are either oxidized by the muscle cells to generate energy. Once the chylomicrons have 
been processed by LPL, the TG depleted chylomicron is called as chylomicron remnants 
which is the transported into the liver.48 
 
VERY LOW DENSITY LIPOPROTEIN 
 
VLDL is a triglyceride rich lipoprotein and constitutes about 10% to 15% of total 
serum cholesterol. VLDL is produced in liver and intestine and is responsible for the 
transport of endogenous triglycerides. It is made up of 50% to 65% triglyceride, 8% to 
14% cholesteryl ester, 12% to 16% phospholipids, 4% to 7% free cholesterol and 5% to 
10% apolipoprotein. Excess carbohydrate diet increases triglyceride synthesis of liver 
resulting in increased production of VLDL. VLDL transports endogenous triglycerides, 
 phospholipids, cholesterol, and cholesteryl esters. It functions as the body's internal 
transport mechanism for lipids.49 
 
INTERMEDIATE DENSITY LIPOPROTEIN 
 
Intermediate-density lipoproteins are the remnant lipoproteins which are the 
lipolytic products of catabolism of the VLDL. They are cleared from the plasma into 
the liver by receptor-mediated endocytosis, or further degraded to form LDL particles. It 
transports a variety of triglyceride fats and cholesterol and, like LDL, can also promote the 
growth of atheroma.50 
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LOW DENSITY LIPOPROTEIN 
 
LDL is formed from VLDL in the blood circulation and liver. They are involved in 
the transport of cholesterol from liver to other tissues. They contain 50% cholesterol. It is 
made up of 35% to 45% cholesteryl esters, 6% to 15% free cholesterol, 22% to 26% 
phospholipids, 4% triglycerides and 22% to 26% apolipoprotein. LDL is the major 
atherogenic lipoprotein, and is the primary target for cholesterol lowering therapy. LDL is 
the primary plasma lipid carrier with a single apolipoprotein (apo) molecule B-100 per one 
particle. 
 
LDL is oxidized in micro domains in the arterial wall where it is sequestered by 
proteoglycans and other extra cellular matrix constituents and protected from plasma 
antioxidants. Oxidized LDL has been shown to be chemotactic and may recruit monocytes 
into the arterial wall where they can be transformed into foam cells. Oxidized LDL can 
also be cytotoxic which damage the endothelial cells and promote cellular secretion of 
several potentially atherogenic molecules. 
 
HIGH DENSITY LIPOPROTEIN 
 
High density Lipoproteins are secreted from the liver as disk-shaped nascent 
particles that consist primarily of phospholipids, apo A-I and apo AII. HDL constitutes 
about 20% to 30% of total serum cholesterol. It is thought to protect against the 
development of atherosclerosis. They are involved in reverse cholesterol transport. They 
contain 25% to 30% phospholipids, 15% to 20% cholesteryl esters, 5% free cholesterol, 
3% triglyceride and 45% to 59% apolipoprotein. There are three subtypes of HDL, in 
which HDL is considered to be the most antiatherogenic HDL subtype.51 
 
1.5. LIPIDPROTEIN METABOLISM 
 
 
The Pathways of lipoprotein metabolism are complex.52, 53, 54 They include 
Exogenous pathway and Endogenous pathways based on whether they carry lipids of 
dietary or hepatic origin and other pathways such as the Intracellular LDL receptor 
pathway and the HDL Reverse cholesterol pathway. 
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Fig No: 1 
Lipid Synthesis, Metabolism and Transport 
Exogenous (Dietary) Lipid Pathway:  
 
Following digestion and absorption of dietary fat, TG and cholesterol are packaged 
to form chylomicrons in the epithelial cells of the intestine. Nascent Chylomicrons are 
assembled from dietary triglycerides and cholesterol in the enterocytes and packaged in 
secretory vesicles in the Golgi apparatus. These particles are then transported by 
exocytosis and introduced into circulation through the intestinal villi. On entering the 
circulation, these acquire the C apolipoproteins and apo E from circulating HDL. The Apo 
C activates the LPL attached to the luminal surface of endothelial cells, which rapidly 
hydrolyzes the triglycerides into free fatty acids. The fatty acids are either taken up by 
muscle cells as an energy source or into adipose cells for storage.55 
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Endogenous Pathway:  
 
The endogenous pathway involves the liver synthesizing lipoproteins. TG and 
cholesterol esters are generated by the liver and packaged into VLDL particles and then 
released into the circulation. VLDL is then processed by LPL in tissues to release fatty 
acids and glycerol. Once processed by LPL, the VLDL becomes a VLDL remnant. The 
majority of the VLDL remnants are taken up by the liver via the LDL receptor, and the 
remaining remnant particles become IDL, a smaller, denser lipoprotein than VLDL. The 
fate of some of the IDL particles requires them to be reabsorbed by the liver (again by the 
LDL receptor). However, other IDL particles are hydrolyzed by hepatic-triglyceride lipase 
to form LDL, a smaller, denser particle than IDL. LDL is the main carrier of circulating 
cholesterol within the body. 
 
Low Density Lipoprotein Receptor Pathway: 
 
Specific receptors present in coated pits on plasma membranes recognize and bind 
apo B-100 of LDL. The LDL particles are internalized in coated vesicles, which then fuse 
to form an endosome. LDL dissociates from the receptor, which returns to the cell surface 
for reuse, whereas LDL migrates to the lysosome. Once the LDL is delivered to the 
lysosome, apo B-100 is degraded to small peptides and amino acids. 
 
LDL is also taken up by extra hepatic tissue through scavenger receptors or non-
receptor mediated pinocytosis. Macrophages that become enlarged with cholesteryl esters 
are called “foam cells”, and are considered the earliest components of the atherosclerotic 
lesion.56 
 
High-Density Lipoprotein Reverse Cholesterol Transport Pathway: 
 
Reverse cholesterol transport refers to the process by which cholesterol is removed 
from the tissues and returned to the liver. HDL is the key lipoprotein involved in reverse 
cholesterol transport and the transfer of cholesteryl esters between lipoproteins.  
 
Through the extracellular addition of surface components of triglyceride-rich 
particles, such as phospholipids, cholesterol and certain apolipoproteins, nascent HDL is 
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converted to spherical particles. Free cholesterol from cell membranes is also transferred 
to the nascent HDL. Cholesterol is esterified by the action of LCAT in the presence of its 
cofactor apo A-I. The size of the HDL depends on the amount of accumulated cholesteryl 
esters and the activity of LCAT. Lysolecithin, a byproduct of this reaction is then removed 
from circulation after binding with albumin. HDL cholesteryl esters are delivered to the 
liver by one of the following mechanisms: (1) cholesteryl esters are selectively taken up 
from HDL by the HDL receptors and the HDL particles are returned to circulation for 
further transport. (2) cholesteryl esters are transferred from HDL to apo B-100 and then 
taken up by the liver. (3) HDL apo E can be recognized by the hepatic remnant receptors. 
These processes constitute the reverse cholesterol transport mechanism, by which cellular 
and lipoprotein cholesterol is delivered back to the liver for reuse or disposal.53 
                        
1.6. LIPOPROTEIN DISORDERS 
 
There are five primary inherited lipoprotein disorders which disturb lipid metabolism. 
 
 These are: 
 
1. Familial Hypertriglyceridemia (FHTG) 
It includes lipoprotein lipase (LPL) deficiency, in which low LPL activity 
results in decreased removal, and thus increases of serum triglyceride, there is 
increased hepatic secretion and thus raised plasma concentration of triglyceride-
rich VLDL. Patients are at risk of recurrent acute pancreatitis when plasma 
triglyceride exceeds 10mmol/l, and especially 20mmol/l. 
 
2. Familial combined hyperlipidemia (FCHL)  
It is common and most important in which there is increased hepatic 
secretion of apolipoprotein B containing VLDL, and conversion to LDL, in 
consequence plasma LDL and VLDL are raised. Patients exhibit macro vascular 
disease. 
 
3. Remnant removal disease (RRD)   
It is also called remnant lipaemia, in which there is a defect of 
apolipoprotein E. This is the major ligand that allows internalization and 
subsequent metabolism of remnant particles derived from VLDL and 
                                                                                                                                             Introduction 
 
Department of Pharmacy Practice    15 
 
chylomicrons. The consequence is accumulation of VLDL remnants called 
intermediarte density lipoprotein (IDL) with cholesterol and triglycerides. Patients 
experience severe macrovascular disease. 
 
4. Familial hypoalphalipoproteinemia (rare)  
In which the serum concentration of HDL is low. 
 
5. Familial hypercholesterolemia (FH)   
Characterized by elevation of total and LDL cholesterol in plasma. LDL 
cholesterol is elevated from childhood. The principal consequence is coronary 
heart disease, but occasionally also peripheral and cerebrovascular disease. It is due 
to defective LDL receptors or mutation in ligand region of apo B-100.57 
 
1.7. CONSEQUENCES OF LIPID ABNORMALITIES57 
 
 Dyslipidemia is a major risk factor for atherosclerosis. Atherosclerosis is a disease 
process that affects the coronary, cerebral and peripheral arterial circulation. 
 
Coronary Heart Disease (CHD) 
 
The etiology of atherosclerosis is multifactorial but the cause-effect relationship 
between dyslipidemia and atherosclerosis has been shown in many studies and trials. 
   
The reducing the plasma LDL cholesterol levels sharply reduces the risk of 
subsequent clinical CHD in both patients with pre-existing CHD and in patients free of 
CHD. There is no doubt about the atherogenicity of LDL. Evidence suggests that oxidative 
modification of LDL within the artery is necessary for mediating its atherogenicity. 
 
An atherogenic lipoprotein pattern, characterized by a predominance of small 
dense LDL, moderately elevated plasma triglycerides and low HDL levels, is the most 
powerful risk factor for CAD. 
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Stroke 
Stroke is a term that describes a clinical event caused either by occlusion or 
hemorrhage in the arterial supply to the central nervous system resulting in tissue 
infarction. It is one of the most devastating consequences of vascular disease. Atheroma 
formation is the root of pathogenesis of thromboembolic stroke. 
 
Peripheral Artery Disease (PAD) 
 
Peripheral artery disease is most commonly a manifestation of systemic 
atherosclerosis in which the arterial lumen of the lower extremities becomes progressively 
occluded by atherosclerotic plaque. High lipoprotein concentrations are important in the 
development of PAD.     
 
Evidence that atherosclerosis in the peripheral circulation should be considered in 
the same manner as atherosclerosis in the coronary circulation. Patients with PAD, even in 
the absence of a history of myocardial infarction or stroke, have approximately the same 
relative risk of death from cardiovascular causes as do patients with a history of coronary 
or cerebrovascular disease. 
 
1.8. CLINICAL PRESENTATION 
 
Dyslipidemia usually causes no symptoms but can lead to symptomatic vascular 
disease, including coronary artery disease (CAD) and peripheral arterial disease. 
 
¾ High levels of TGs (> 1000 mg/dL [> 11.3 mmol/L]) can cause acute pancreatitis. 
High levels of LDL can cause eyelid xanthelasmas, arcus corneae, and tendinous 
xanthomas at the Achilles, elbow, and knee tendons and over metacarpophalangeal 
joints.  
¾ Patients with the homozygous form of familial hypercholesterolemia may have the 
above findings plus planar or cutaneous xanthomas. 
¾ Patients with severe elevations of TGs can have eruptive xanthomas over the 
trunk, back, elbows, buttocks, knees, hands, and feet.  
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¾ Patients with the rare dysbetalipoproteinemia can have palmar and tuberous 
xanthomas. 
¾ Severe hypertriglyceridemia can give retinal arteries and veins a creamy white 
appearance (lipemia retinalis). Extremely high lipid levels also give a milky 
appearance to blood plasma. 
 
Diagnosis 
 
Dyslipidemia is diagnosed by measuring serum profile which consists of total 
cholesterol, TG, and HDL cholesterol and calculated LDL cholesterol and VLDL. 
 
1.9. ASSESSMENT OF LIPID PROFILE 
 
TC, TGs, and HDL cholesterol are measured directly. TC and HDL cholesterol can 
be measured in the nonfasting state, but most patients should have all lipids measured 
while fasting for maximum accuracy and consistency.  
 
LDL cholesterol values are most often calculated as the amount of cholesterol not 
contained in HDL and VLDL. VLDL is estimated by TG ÷ 5 because the cholesterol 
concentration in VLDL particles is usually 1/5 of the total lipid in the particle. Thus, LDL 
cholesterol = TC − [HDL cholesterol + (TGs ÷ 5)] (Friedewald formula). This calculation 
is valid only when TGs are< 400 mg/dL and patients are fasting, because eating increases 
TGs.  
 
LDL can also be measured directly using plasma ultracentrifugation, which 
separates chylomicrons and VLDL fractions from HDL and LDL, and by an immunoassay 
method. Direct measurement may be useful in some patients with elevated TGs, but these 
direct measurements are not routinely necessary.58 
 
1.10. MANAGEMENT OF DYSLIPIDEMIA 
 
 
The NCEP guidelines recommend that patients at higher risk of coronary heart disease 
receive more intensive interventions for dyslipidemia than patients at lower risk.59 The 
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ATP III Classification of LDL, Total and HDL Cholesterol and Triglycerides (mg/dL) is 
shown in Table No: 5 
TABLE NO: 5 
 
 
Two approaches to therapy are available: lifestyle changes and drug therapy: 
 
¾ Lifestyle changes are the first step of treatment of dyslipidemia. These include 
dietary changes, smoking cessation, weight loss (if overweight), and exercise. 
These changes may reduce cardiovascular disease risk independent of their 
influence on lipid levels. 
 
¾ Drug therapy should be reserved for those with known CVD and those patients at 
increased CVD risk failing to reach LDL-C targets with lifestyle modifications. 
Statins have been shown to be cost effective in both these populations. 
 
LIFESTYLE MODIFICATIONS 
 
The NCEP guidelines recommend dietary modification, exercise and weight 
control as the foundation of treatment of dyslipidemia. Cessation of cigarette smoking and 
reduction of other modifiable risk factors are essential aspects of prevention of coronary 
heart disease.60 
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EXERCISE AND WEIGHT REDUCTION 
 
Obesity frequently elevates cholesterol levels in both very-low-density lipoprotein 
(VLDL) and LDL fractions, raises triglyceride levels, lowers HDL cholesterol levels, 
raises blood pressure and promotes glucose intolerance. Thus Overweight patients should 
engage in low-intensity exercise more frequently and for longer durations.61 
 
ALCOHOL INTAKE 
Alcohol exerts several effects on lipid levels, including raising the serum 
triglyceride and HDL cholesterol levels. Its effect on LDL cholesterol appears to be 
minimal. The intake of alcohol stimulates the synthesis of triglycerides by the liver. Thus 
high intake of alcohol usually cause a moderate rise in triglyceride levels, but in patients 
with an underlying hypertriglyceridemia, the response can be marked i.e., severe 
hypertriglyceridemia may develop. Thus it is not recommended for the prevention of 
coronary heart disease.62 
DIETARY FIBER 
Soluble fiber has been shown to modestly reduce total cholesterol and LDL 
cholesterol levels. Current dietary guidelines recommend a total daily fiber intake of at 
least 20 to 30 g for adults, with 25 percent of the fiber being soluble fiber. These levels can 
be attained with the proposed six or more daily servings of grain products and five or more 
daily servings of fruits and vegetables.  
ANTIOXIDANTS 
 
Atherogenicity is promoted by oxidation and glycosylation of LDL 
cholesterol. Several vitamins, including vitamin C, vitamin E and β-carotene, have 
antioxidant properties, which may provide protection against atherogenesis. Fruits and 
dark-green and deep-yellow vegetables are rich sources of antioxidant vitamins. Thus the 
use of antioxidants prevents the formation of oxidized LDL. 
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DRUG THERAPY 
Because dietary modification rarely reduces LDL cholesterol levels by more than 
10 to 20 %, the NCEP guidelines recommend that consideration be given to the use of 
cholesterol-lowering agents if lipid levels remain elevated after six months of intensive 
dietary therapy or sooner under certain circumstances.63 
A patient with a very high LDL cholesterol level may need to start drug therapy 
sooner, because it is unlikely that a patient with an LDL level of 130 mg/dL (3.35 mmol 
per L) or greater will be able to achieve the goal of 100 mg/dL (2.60 mmol per L) with diet 
alone.64 
The currently available lipid-lowering drugs can be divided into the statins, the bile 
acid sequestrants, nicotinic acid, the fibrates, and cholesterol absorption inhibitors. These 
all reduce LDC-C. Of these drugs, statins with their relatively few side effects and 
predictable benefits for treating LDC-C are now usually the drugs of first choice. They are 
highly effective in reducing total cholesterol and LDC-C, they usually increase HDL-C, 
and long term safety and efficacy are now established. The lipid lowering drugs with their 
side effects and contraindications are shown in Table No:6 
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Table No: 6 Drugs Affecting Lipoprotein Metabolism 
Drug Class Lipid/Lipoprotein Effects Side Effects Contraindications 
HMG – CoA 
reductase inhibitos 
(Statins)  
Simvastatin 
Atorvastatin 
Rosuvastatin 
Lovastatin 
Pravastatin  
Fluvastatin  
LDL ↓18-55% 
HLD ↑5-15% 
TG ↓7-30% 
Myopathy, 
Increased liver 
enzymes   
Active or chronic liver 
disease  
Fibric acids 
(Fibrates) 
Fenofibrate, 
Bezafibrate 
Clofibrate 
Gemfibrozil 
LDL (may be increased in 
patients with high TG)  
↓5-20% 
HDL ↑10-20% 
TG ↓ 20-50% 
Dyspepsia, 
Gallstones, 
Myopathy 
Severe renal disease  
Nicotinic acid 
(Niacin) 
LDL ↓ 5-25% 
HDL ↑15-35% 
TG ↓20-50% 
Flushing, 
Hyperglycemia, 
Hyperuricemia 
Chronic liver disease  
Cholesterol 
Absorption 
Inhibitors (CAI) 
 Ezetimibe 
LDL ↓17% 
HDL – Minimal change  
TG – minimal change  
Angioedema, 
Headache 
Hypersensitivity  
Bile acid 
Sequestrants (BAR) 
Cholestyramine 
Colestipol  
LD ↓15-30% 
HDL ↑3-5% 
TG no change or increase  
Gastrointestinal 
distress  
 
Dysbetaliporoteinemia  
 
STATINS 
The statins are the most effective and best tolerated agents for treating 
dyslipidemia. These drugs are used to lower cholesterol levels by inhibiting the 
enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol 
in the liver.65 Statins have anti atherosclerotic effects, that correlate positively with the 
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percent decrease in LDL cholesterol. In addition, they can exert antiatherosclerotic effects 
independently of their hypolipidemic action. This is because mevalonate metabolism 
generates a series of vital isoprenoids for different cellular functions, from cholesterol 
synthesis to the control of cell growth and differentiation. Also, statins significantly reduce 
the incidence of coronary events, both in primary and secondary prevention, being the 
most efficient hypolipidemic compounds that have reduced the rate of mortality in 
coronary patients. Beyond lipid-lowering activity, Statins exhibit actions like: 
¾ Improve endothelial function 
¾ Modulate inflammatory responses 
¾ Maintain plaque stability 
¾ Prevent thrombus formation 
History 
The identification of inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase led to the class of drugs known as statins. The 
discovery culminated in the labs of Dr. Akira Endo at Sankyo in Japan in the early 1970s. 
The first statin isolated was mevastatin (ML-236B), a molecule produced by the 
fungus ''Penicillium citrinum''. Mevastatin was never marketed, because of its adverse 
effects of tumors, muscle deterioration, and death observed in laboratory dogs. 
In 1978, Merck & Company isolated their first statin (initially called mevinolin, 
monacolin K, and MK803) from Aspergillus terreus. In 1987, Merck & Company 
launched the statin lovastatin (Mevacor).66 
The statins are divided into two groups: fermentation derived and synthetic. 
Lovastatin, Simvastatin, Pravastatin are derived from fungi while Fluvastatin, 
Atorvastatin, and Rosuvastatin are synthetic. All statins share an HMG-CoA like moiety, a 
dihydroxy hepatanoic acid, which competes with HMG-CoA for binding with HMG-CoA 
reductase.  
Mechanism of Action 
 
Statins inhibit HMG-CoA reductase, the enzyme that converts HMG-CoA into 
mevalonic acid, a cholesterol precursor. They alter the conformation of the enzyme when 
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they bind to its active site. This prevents HMG-CoA reductase from attaining a functional 
structure. The change in conformation at the active site makes these drugs very effective 
and specific. Binding of statins to HMG CoA reductase is reversible, and their affinity for 
the enzyme is in the nanomolar range, as compared to the natural substrate, which has 
micromolar affinity.67 
 
The inhibition of HMG-CoA reductase determines the reduction of intracellular 
cholesterol, inducing the activation of a protease which slices the sterol regulatory element 
binding proteins (SREBPs) from the endoplasmic reticulum. SREBPs are translocated at 
the level of the nucleus, where they increase the gene expression for LDL receptor. The 
reduction of cholesterol in hepatocytes leads to the increase of hepatic LDL receptors, that 
determines the reduction of circulating LDL and of its precursors (intermediate density - 
IDL and very low density- VLDL lipoproteins).68 All statins reduce LDL cholesterol non-
linearly, dose-dependent, and after administration of a single daily dose.69 
 
Administration 
 
Patients should be started on therapeutic lifestyle changes, such as diet and 
exercise, prior to the initiation of statin therapy. Statins are best given once daily in the 
evening to coincide with the cholesterol biosynthesis at night. It is recommended that 
lovastatin be administered with food to enhance its absorption, but the other statins may be 
taken with or without food. The LDL cholesterol-lowering effect may be seen within two 
weeks of initiating therapy, but may take as long as six weeks to be achieved with 
atorvastatin or rosuvastatin.70 
 
Side Effects of Statin Therapy 
 
Statins are generally well tolerated. The most important adverse effects are liver 
and muscle toxicity. 
 
Drug-induced liver injury is uncommon, but in rare circumstances it may lead to 
liver failure. It is typically classified as either hepatocellular or cholestatic. Elevations in 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) indicate liver cell 
damage, whereas elevations in total bilirubin, alkaline phosphatase, and gamma-glutamyl 
transferase (GGT) reflect cholestasis. Injury from statins is hepatocellular and is therefore 
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indicated by elevations in AST and ALT levels. These elevations are usually 
asymptomatic and transient and resolve after discontinuation of the drug. Thus liver 
enzymes should be monitored in all patients who take statins. If the alanine 
aminotransferase (ALT) or aspartate aminotransferase (AST) level doubles, the statin 
should be stopped.71 
 
The most common side effect associated with statins is myalgia. The exact 
mechanism is unknown. One hypothesis is that statins reduce the cholesterol content of the 
sarcolemma of skeletal muscle cells which may lead to instability or even rupture of some 
muscle cells.72 Another hypothesis states that statins interfere with the formation of 
ubiquinone (also called coenzyme Q10), a byproduct of cholesterol synthesis. Since 
ubiquinone plays an important role in the cellular energy transduction of the mitochondrial 
electron transport system, decreased levels of ubiquinone may cause myotoxicity.73 The 
other risk factors for the occurrence of muscle toxicity are increasing dose, advanced age, 
female gender, hepatic dysfunction, hypothyroidism, and concurrent use of agents such as 
cytochrome P450 inhibitors, azole antifungals, Fibrates and niacin etc. Thus statins should 
be discontinued in patients who develop intolerable muscle symptoms. 74 
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 DRUG PROFILE-I 
 
ATORVASTATIN CALCIUM 
BRAND NAME: Storvas, Lipitor 
 
CHEMICAL NAME: 
Atorvastatin calcium is [R-(R*, R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-
methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1Hpyrrole-1-heptanoic acid, calcium 
salt (2:1) trihydrate. 
EMPIRICAL FORMULA:  (C33H34FN2O5)2Ca•3H2O 
 
MOLECULAR WEIGHT is 1209.42. 
 
STRUCTURAL FORMULA: 
 
 
DESCRIPTION 
 
Storvas is a synthetic lipid-lowering agent. Atorvastatin is an inhibitor of 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the 
conversion of HMG-CoA to mevalonate, an early and rate-limiting step 
in cholesterol biosynthesis. 
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Atorvastatin calcium is very slightly soluble in distilled water, pH 7.4 phosphate 
buffer, and acetonitrile, slightly soluble in ethanol and freely soluble in methanol. 
 
CLINICAL PHARMACOLOGY 
 
Mechanism of action: 
 
STORVAS (atorvastatin calcium) is a synthetic lipid-lowering agent. It is a 
selective, competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase, rate-limiting step in the biosynthesis of cholesterol. It lowers plasma cholesterol 
and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the 
liver and by increasing the number of hepatic Low Density Lipoprotein (LDL) receptors 
on the cell-surface for enhanced uptake and catabolism of Low Density Lipoprotein 
(LDL).It also reduces Very Low Density Lipoprotein-Cholesterol (VLDL-C), serum 
triglycerides (TG) and Intermediate Density Lipoproteins (IDL), as well as the number of 
apolipoprotein B (apo B) containing particles, but increases High Density Lipoprotein-
Cholesterol (HDL-C). Elevated serum cholesterol due to elevated LDL-C is a major risk 
factor for the development of cardiovascular disease. Low serum concentration of HDL-C 
is also an independent risk factor. Elevated plasma TG is also a risk factor for 
cardiovascular disease, particularly if due to increased IDL, or associated with decreased 
HDL-C or increased LDL-C. 
 
PHARMACOKINETICS 
 
Absorption:  
Atorvastatin is rapidly absorbed after oral administration, maximal plasma 
concentrations occur within 1 to 2 hours. Extent of absorption and plasma atorvastatin 
concentrations increase in proportion to atorvastatin dose. Atorvastatin tablets are 95-99% 
bioavailable compared to solutions. The absolute bioavailability (parent drug) of 
atorvastatin is approximately 12% and the systemic availability of HMG-CoA reductase 
inhibitory activity is approximately 30%. The low systemic availability is attributed to 
presystemic clearance in gastrointestinal mucosa and first-pass metabolism in the liver. 
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Distribution:  
Mean volume of distribution of atorvastatin is approximately 381 liters. 
Atorvastatin is 98% bound to plasma proteins. 
 
Metabolism:  
Atorvastatin is extensively metabolized to ortho- and para-hydroxylated derivatives 
by cytochrome P-450 3A4 (CYP 3A4) and to various β-oxidation products. Approximately 
70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active 
metabolites. 
 
Excretion:  
Atorvastatin is eliminated primarily in bile following hepatic and or extrahepatic 
metabolism. However, the drug does not appear to undergo significant enterohepatic 
recirculation. Mean plasma elimination half-life of atorvastatin in humans is 
approximately 14 hours, but the half-life for inhibitory activity for HMG-CoA reductase is 
20 to 30 hours due to the contribution of longer-lived active metabolites. Less than 2% of a 
dose of atorvastatin is recovered in urine following oral administration. 
 
DOSAGE FORMS:              
Tablets are formulated for oral administration and are available in tablet doses of 
10 mg, 20 mg, 40 mg and 80 mg. 
 
INDICATION: 
Adjunct to lifestyle changes, including diet, for the reduction of elevated total 
cholesterol (total-C), LDL-C, triglycerides (TG), apolipoprotein B (apo B), the Total-
C/HDL-D ratio and for increasing HDL-C in hyperlipidemic and dyslipidemic conditions. 
 
CONTRAINDICATIONS & PRECAUTIONS: 
Contraindicated in patient’s hypertensive to drug with Active liver disease, 
unexplained persistent elevations of serum transaminase levels, in pregnant or breast 
feeding women and in women of child bearing. Use cautiously in patients with history of 
hepatic disorder and heavy alcohol use. 
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SPECIAL POPULATIONS: 
 
Pediatrics:  
Pharmacokinetic data in the pediatric population are not available. 
 
Geriatrics:  
Plasma concentrations of atorvastatin are higher (approximately 40% for Cmax and 
30% for AUC) in healthy elderly subjects (age 65 years or older) compared with younger 
individuals. LDL-C reduction, however, is comparable to that seen in younger patient 
populations. 
 
Gender:  
Plasma concentrations of atorvastatin in women differ (approximately 20% higher 
for Cmax and 10% lower for AUC) from those in men, however, there is no clinically 
significant difference in LDL-C reduction between men and women.  
 
Race:  
Plasma concentrations of atorvastatin are similar in black and white subjects. 
 
Hepatic Insufficiency:  
Plasma concentrations of atorvastatin are markedly increased (approximately 16-
fold in Cmax and 11-fold in AUC) in patients with chronic alcoholic liver disease. 
 
DRUG INTERACTIONS: 
 
¾ Strong Inhibitors of CYP 3A4 
Atorvastatin calcium is metabolized by cytochrome P450 3A4. Concomitant 
administration of Atorvastatin calcium with strong inhibitors of CYP3A4 
(clarithromycin, HIV protease inhibitors, and itraconazole) can lead to increase 
in plasma concentrations of atorvastatin. 
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¾ Grapefruit Juice 
Contains one or more components that inhibit CYP 3A4 and can increase plasma 
concentrations of atorvastatin, especially with excessive grapefruit juice consumption (> 
1.2 liters per day). 
¾ Digoxin 
Plasma digoxin concentrations increased by approximately 20%.  
 
STORAGE: 
 
Store at controlled room temperature 15 to 30ºC. 
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DRUG PROFILE-II 
 
 SIMVASTATIN 
BRAND NAME: ZOCOR 
 
CHEMICAL NAME 
Simvastatin is butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-
(tetrahydro-4hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-
[1α,3α,7β,8β(2S*,4S*),-8aβ]]. 
EMPIRICAL FORMULA:  C25H38O5 
MOLECULAR WEIGHT   :  418.57 
STRUCTURAL FORMULA: 
 
 
DESCRIPTION 
 
ZOCOR (simvastatin) is a lipid-lowering agent that is derived synthetically from a 
fermentation product of Aspergillus terreus. After oral ingestion, simvastatin which is an 
inactive lactone is hydrolyzed to the corresponding β-hydroxyacid form. This is an 
inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This 
enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate 
limiting step in the biosynthesis of cholesterol. 
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Simvastatin is a white to off-white, non-hygroscopic, crystalline powder that is 
practically insoluble in water, and freely soluble in chloroform, methanol and ethanol. 
 
CLINICAL PHARMACOLOGY 
 
Mechanism of action: 
 
Simvastatin is a prodrug and is hydrolyzed to its active hydroxyacid, simvastatin 
acid form. Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A 
(HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to 
mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol. In 
addition, simvastatin reduces VLDL and TG and increases HDL-C. 
 
PHARMACOKINETICS 
 
Absorption:  
Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding β-
hydroxyacid, a potent inhibitor of HMG-CoA reductase. Inhibition of HMG-CoA 
reductase is the basis for an assay in pharmacokinetic studies of the β-hydroxyacid 
metabolites (active inhibitors) and following base hydrolysis, active plus latent inhibitors 
(total inhibitors) in plasma following administration of simvastatin. 
 
.  
Distribution:  
Both simvastatin and its β-hydroxyacid metabolite are highly bound 
(approximately 95%) to human plasma proteins. 
 
 
Metabolism:  
The major active metabolites of simvastatin present in human plasma are the β-
hydroxyacid of simvastatin and its 6′-hydroxy, 6′-hydroxymethyl, and 6′-exomethylene 
derivatives. Peak plasma concentrations of both active and total inhibitors were attained 
within 1.3 to 2.4 hours post dose. 
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Excretion:  
Following an oral dose, 13% of the dose was excreted in urine and 60% in faeces. 
 
DOSAGE FORMS: 
The usual dosage range is 5 to 40 mg/day. 
 
INDICATIONS: 
 Adjunct to lifestyle changes, including diet, for the reduction of elevated total 
cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo 
B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in 
patients with primary hyperlipidemia. 
 
CONTRAINDICATIONS & PRECAUTIONS 
Contraindicated in patient’s hypertensive to drug with Active liver disease, 
unexplained persistent elevations of serum transaminase levels, in pregnant or breast 
feeding women and in women of child bearing. 
 
SPECIAL POPULATIONS 
 
Pediatrics:  
Simvastatin has not been studied in patients younger than 10 years of age, or in 
pre-menarcheal girls. 
 
Geriatrics:  
Since advanced age (≥65 years) is a predisposing factor for myopathy, including 
rhabdomyolysis, Zocor should be prescribed with caution in the elderly. 
 
Hepatic Impairment:  
Zocor is contraindicated in patients with active liver disease which may include 
unexplained persistent elevations in hepatic transaminase levels. 
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DRUG INTERACTIONS 
 
Simvastatin is metabolized by the cytochrome P450 isoform 3A4. Certain drugs 
which inhibit this metabolic pathway can raise the plasma levels of simvastatin and may 
increase the risk of myopathy. These include itraconazole, ketoconazole, and the macrolide 
antibiotics erythromycin and clarithromycin, and the ketolide antibiotic telithromycin, HIV 
protease inhibitors, the antidepressant nefazodone, or large quantities of grapefruit juice 
(>1 quart daily). 
 
The combined use of simvastatin with gemfibrozil, cyclosporine, or danazol is 
contraindicated as these agents can cause myopathy when given alone and the risk is 
increased when they are co-administered. 
 
STORAGE: 
 
Store at controlled room temperature 5 to 30ºC. 
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REVIEW OF LITERATURE 
 
¾ Jason. P. Swindle, et al75., examined differences in drug utilization and CV event 
risk among elderly patients newly initiated on simvastatin versus atorvastatin. 
 Enrollees aged ≥65 years, newly initiated on simvastatin or Atorvastatin from July 
1, 2006 to November 30, 2008 were identified for study inclusion. Patients were 
excluded if they had any prescriptions for clopidogrel, nitrates, or other 
dyslipidemia medication, or any CV events before index drug initiation. Adherence 
was calculated by proportion of days covered with index medication. The majority 
of patients started on low-dose therapy and did not achieve sufficient adherence. 
After controlling for patient and clinical characteristics, no statistically significant 
difference in risk of CV event was observed based on initiation 
with atorvastatin versus simvastatin. 
 
¾  Jennifer. G. Robinson, et al76., assessed percent change from baseline in lipids 
and high-sensitivity C-reactive protein (hs-CRP) levels and the proportion of 
subjects reaching specified low-density lipoprotein cholesterol (LDL-C), non-high-
density lipoprotein cholesterol (HDL-C) and apolipoprotein B (Apo B). Adults 
(N = 1143) with Metabolic syndrome and hypercholesterolemia were randomized 
to starting and next higher doses of ezetimibe/simvastatin (10/20 or 10/40 mg) 
or atorvastatin (10, 20, or 40 mg). More intensive therapy was required for >80% 
of subjects to achieve LDL-C <100 mg/dL and non-HDL-C <130 mg/dL and for 
the majority of subjects to achieve lower levels of LDL-C <70 mg/dL, non-HDL-C 
<100 mg/dL, and/or Apo B <90 mg/dL. The effect of ezetimibe on cardiovascular 
risk reduction has yet to be established. 
 
¾ Amy Furman, et al77., carried out a Retrospective study in Veterans Affairs 
Health Care System over a 3-year time period. The primary objective of this study 
was to determine the LDL-lowering efficacy of higher-potency strategies 
(ezetimibe/simvastatin, rosuvastatin, and atorvastatin) in high-risk patients who 
were switched from simvastatin therapy. Secondary objectives were to evaluate 
patient adherence to these therapies, determine the efficacy of these interventions 
on other lipid parameters, and define the incidence of adverse effects. Lipid data 
were assessed prior to and within 2 to 6 months following the conversion from 
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simvastatin. Adherence to therapy was determined by medication refill data. At the 
doses used in this population, ezetimibe/simvastatin resulted in greater LDL 
reductions than rosuvastatin or atorvastatin. The clinical impact of these 
differences is as yet undetermined. 
 
¾ James McKenney, et al78., compared the proportion of patients at high risk for 
coronary heart disease (CHD) achieving the recommended low-density lipoprotein 
cholesterol (LDL-C) treatment goal of < 100 mg/dL and the optional LDL-C target 
of < 70 mg/dL with co administration of ezetimibe and simvastatin (EZE/SIMVA) 
Vs either atorvastatin or simvastatin monotherapy. Patients at high risk for CHD 
are more likely to attain LDL-C treatment targets with the usual recommended 
starting dose of EZE/SIMVA (10 or 20 mg) therapy than with that 
of atorvastatin (10 mg) or simvastatin (20 mg) monotherapy. 
 
¾ Samir Maruti Adsule, et al79., evaluated and compared the safety and efficacy 
of rosuvastatin, simvastatin, and atorvastatin in patients of type 2 diabetes mellitus 
with Dyslipidemia. This open-label, randomized, parallel group, comparative, 
prospective study of 12-weeks duration included 60 patients of  type-2 diabetes 
with Dyslipidemia having good glycemic control with fixed dose combination of 
tablet glimepiride + metformin and divided into three groups of twenty each. 10 
mg of rosuvastatin was comparable to 10 mg of atorvastatin and more efficacious 
than 10 mg simvastatin in reducing LDL levels after 12 weeks of therapy in 
patients of type 2 diabetes mellitus with Dyslipidemia. 
 
¾ William Insull Junior, et al80., compared the efficacy and safety of a proprietary 
niacin extended-release and simvastatin (NER/S) combination to atorvastatin 
monotherapy in a multicenter, Prospective, Randomized (3:2), Open-label, Blinded 
Endpoint (PROBE) study. Following ≥4 weeks without lipid-modifying therapies, 
193 patients with dyslipidemia were treated with NER/S (n = 114; 1000/40 
mg/day, weeks 1 to 4; 2000/40 mg/day weeks 5 to 12) or atorvastatin (n = 79; 40 
mg/day, weeks 1 to 12). Compared to atorvastatin, NER/S provided superior 
improvements in HDL-C, TG, and Lp (a) and comparable improvements in non-
HDL-C and LDL-C. Treatment with NER/S should be considered for patients with 
dyslipidemia requiring comprehensive lipid control. 
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¾ Suyog Sindhu, et al81., evaluated and compared the effects on high-sensitivity C-
reactive protein (hs-CRP) levels and lipid profile of atorvastatin and rosuvastatin in 
obese type 2 diabetes mellitus (T2DM) patients. Results obtained from the study, 
clearly indicate that atorvastatin (A) as well as rosuvastatin(R) have significant 
effect on lowering of hs-CRP levels (for A p=0.001; for R p=0.002), reducing 
LDL-C levels (for A p=0.008; for R p=0.001), elevating HDL-C levels (for A 
p=0.02; for R p=0.001) along with reducing TC (for A p=0.003; for R p=0.002) 
and TG (for A p=0.000; for R p=0.000) levels in obese T2DM patients. It is also 
seen that there is no significant (p>0.05) difference in effect 
of atorvastatin and rosuvastatin lowering of hs-CRP levels, elevating HDL-C levels 
and reducing TG levels in obese T2DM patients. Thus this study throws light on 
the fact that rosuvastatin should be preferred over atorvastatin in obese T2DM 
patients in whom LDL-C and TC levels are deviated from normal reference values. 
 
¾ Dagmar Vondrakova, et al82., analyzed a group of 114 patients with ACS (mean 
age 63.7; females 25.4%). Atorvastatin 80 mg was administered at admission and 
then once daily for the rest of hospitalization. The levels of total cholesterol 
(TC), LDL-cholesterol (LDL), HDL-cholesterol (HDL), and triglycerides (TG) 
were measured at admission (D0), and then every morning of hospitalization (D1, 
D2).It is shown that ACS patients has a highly significant, immediate effect on all 
monitored lipid levels. Since TC and LDL levels were decreased as predicted, 
reduction in HDL and increase in TG levels suggest a different acute effect of 
high-dose statin on lipid levels in comparison with long-term treatment of ACS 
patients. 
 
¾ Jong-Seon Park, et al83., compared the effects of rosuvastatin 10 mg 
and atorvastatin 10 mg on lipid and glycemic control in Korean patients with 
nondiabetic metabolic syndrome. This was a multicenter, open-labeled, 
randomized trial performed on 351 patients who met the modified National 
Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria 
for metabolic syndrome with low-density lipoprotein cholesterol (LDL-C) levels > 
or = 130 mg/dL were randomized to receive either rosuvastatin 10 mg (n = 173) 
or atorvastatin 10 mg (n = 178) for over 6 weeks. It was found that Rosuvastatin 10 
mg was more effective than atorvastatin 10 mg in achieving NCEP ATP III LDL-C 
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goals in patients with nondiabetic metabolic syndrome, especially in those with 
lower NCEP ATP III target level goals. 
 
¾ Beth L Abramson, et al84., conducted a study in which Data were combined from 
27 double-blind, active or placebo-controlled studies that randomized adult 
hypercholesterolemic patients to statin or statin+ezetimibe. Consistency of 
treatment effect among men (n = 11,295) and women (n = 10,499) was assessed 
and percent of men and women was calculated to evaluate the between-treatment 
ability to achieve specified treatment levels between sexes. The results suggest that 
small sex-related differences may exist in response to lipid-lowering treatment and 
achievement of specified lipid and hs-CRP levels, which may have implications 
when managing hypercholesterolemia in women. 
 
¾ Larry B. Goldstein, et al85., conducted a randomized trial which is designed to 
determine whether treatment with atorvastatin reduces strokes in subjects with 
recent stroke or transient ischemic attack (n=4731). Severity was assessed with the 
National Institutes of Health Stroke Scale, Barthel Index, and modified Rankin 
Scale score at enrollment (1 to 6 months after the index event) and 90 days 
poststroke in subjects having a stroke during the trial. This study suggests that the 
outcome of recurrent ischemic cerebrovascular events might be improved among 
statin users as compared with nonusers. 
 
¾ Kuan Gandelman, et al86., assessed the efficacy and tolerability of atorvastatin in 
Tanner stage (TS) 1 patients ages 6 to 10 years and TS ≥ 2 patients ages 10 to <18 
years with genetically confirmed heterozygous familial hypercholesterolemia 
(HeFH) and a low density lipoprotein cholesterol (LDL-C) level of 4 mmol/l (155 
mg/dL) or higher. This study suggests tat there was no difference in safety or 
tolerability was observed between the younger and older cohorts. Across the range 
of exposures after atorvastatin 5 to 10 mg (TS 1) or atorvastatin 10 to 20 mg (TS ≥ 
2) doses for 8 weeks, clinically meaningful reductions in LDL-C, TC, VLDL-C, 
and Apo were observed with atorvastatin in pediatric patients who had HeFH. 
Atorvastatin also was well tolerated in this population. 
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¾ Eyal Leibovitz, et al87., had evaluated the effect of atorvastatin on plasma 
fibrinogen levels in patients with severe hypercholesterolemia and no other risk 
factors. Twenty-two patients with low density lipoprotein-cholesterol levels above 
170 mg/dl (4.40mmol/L) and with no other risk factors were included in the study. 
After 24 weeks of follow-up, total cholesterol decreased by 33% (287 +/- 10 to 192 
+/- 8 mg/dl, P < 0.001), LDL-C by 45% (198 +/- 8 to 111 +/- 7 mg/dl, p < 0.001) 
and triglycerides by 21% (189 +/- 26 to 138 +/- 15 mg/dl, P < 0.001). Fibrinogen 
levels dropped by 18% (355 +/- 26 to 275 +/- 7 mg/dl, P = 0.01). CRP levels 
decreased from 0.51 +/- 0.15 to 0.28 +/- 0.10 mg/dl, but the difference was not 
statistically significant (P = 0.09). High density lipoprotein, hemoglobin, white 
blood cell and platelet counts did not change. 
 
¾ Gianluca Bardini, et al88., performed a randomized, double-blind, double-dummy 
study in patients with type 2 diabetes mellitus (T2DM). Adult patients with T2DM 
and CHD (N = 93) on a stable dose of simvastatin 20 mg with LDL-C >or= 2.6 
mmol/L (100 mg/dL) and <or= 4.1 mmol/L (160 mg/dL) were randomized 
to ezetimibe 10 mg plus simvastatin 20 mg (EZ + simva 10/20 mg) or 
simvastatin 40 mg for 6 weeks. Percent change in LDL-C, high-density lipoprotein 
cholesterol, and triglyceride was assessed. The results demonstrate that EZ + 
simvastatin 10/20 mg may provide a superior alternative for LDL-C lowering Vs 
doubling the dose of simvastatin to 40 mg in hyperlipidemic patients with T2DM 
and CHD. In addition, the combination therapy may provide an alternative 
treatment for patients who require further LDL-C reduction than they can achieve 
with simvastatin 20 mg alone. 
 
¾ John J.P. Kastelein, et al89., conducted a double-blind, randomized, 24-month 
trial comparing the effects of daily therapy with 80 mg of simvastatin either with 
placebo or with 10 mg of ezetimibe in 720 patients with familial 
hypercholesterolemia. Patients underwent B-mode ultrasonography to assess the 
intima-media thickness of the walls of the carotid and femoral arteries. The 
primary outcome measured was the change in the mean carotid-artery intima-
media thickness. In patients with familial hypercholesterolemia, combined therapy 
with ezetimibe and simvastatin did not result in a significant difference in changes 
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in intima-media thickness, as compared with simvastatin alone, despite decreases 
in levels of LDL cholesterol and C-reactive protein. 
 
¾ Michel Farnier, et al90., explored the frequency/magnitude of HDL-C reductions 
in a pooled database of mixed dyslipidemic patients (LDL-C: 3.4-5.7 
mmol/L;TG:1.7-5.7 mmol/L) receiving placebo (PBO), fenofibrate 
(FENO), ezetimibe plus FENO (EZE+FENO), or EZE/simvastatin plus FENO 
(EZE/SIMVA+FENO) for 12 weeks. PBO-treated patients had the highest 
incidence of HDL-C reductions from baseline (45%) compared with patients taking 
FENO (14%), EZE+FENO (9%), or EZE/SIMVA+FENO (9%). The incidence of 
paradoxical HDL-C reductions was low in mixed dyslipidemic patients receiving 
FENO alone or combined with EZE or EZE/SIMVA. 
 
¾ Dong Kyun Kim, et al 91., carried out a retrospective study to evaluate the efficacy 
of 10 mg dosage of atorvastatin in a clinical setting. One hundred five enrolled 
patients with high levels of low density lipoprotein cholesterol (LDL-C, > 100 
mg/dL) took 10 mg atorvastatin. After 6 months, they were divided into Responder 
group (LDL-C < 100 mg/dL) and Non-responder group (LDL-C ≥ 100 mg/dL), and 
the response rate was calculated. Thereafter, we subdivided the Responder group 
into Maintenance (10 mg), Reduced dosage (5 mg), and Discontinuance group (0 
mg). The Non-Responder group was subdivided into Maintenance (10 mg) and 
Double dosage group (20 mg). After consecutive 6 months, the response rates of 
each 10 mg Maintenance groups were compared to those of the other groups, 
respectively. Hypercholesterolemia treatment with 10 mg, fixed dosage 
of atorvastatin was effective in three quarters of the subjects during the first 6-
month treatment; however, a significant number of patients with high LDL-C 
levels and/or BMI require higher starting and maintenance dosage. 
 
¾ Thozhukat Sathyapalan, et al92., compared the effect of equivalent LDL-
lowering doses of simvastatin and atorvastatin on hsCRP in type 2 diabetic 
patients. A crossover study of 26 patients with type 2 diabetes taking either 40mg 
simvastatin or 10 mg atorvastatin was undertaken. After 3 months on one statin, 
lipids and hsCRP were measured on 10 occasions over a 5-week period. The same 
procedure was then followed taking the other statin. The results showed that 
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compared with simvastatin, atorvastatin reduced hsCRP and its variability in type 2 
diabetic patients. 
 
¾ Carlo M Rotella, et al93., conducted a randomized double blind study. After 
stabilization on simvastatin 20 mg, patients with coronary heart disease (CHD) 
alone and/or type 2 diabetes mellitus (T2DM) were randomized to ezetimibe 10 
mg/simvastatin 20 mg (EZ/Simva) or simvastatin 40 mg. EZ/Simva treatment (N = 
93) resulted in significantly greater reductions in LDL-C, TC, and TC/HDL-C ratio 
and higher attainment of LDL-C < 2.6 mmol/L Vs doubling the simvastatin dose to 
40 mg (N = 106). Study [including diabetic patients (OR = 2.9, p = 0.003)], 
EZ/Simva treatment (OR = 6.1, p < 0.001), and lower baseline LDL-C (OR = 0.9, 
p = 0.001) were significant positive predictors of LDL-C target achievement. When 
baseline LDL-C was expressed as a discrete variable, the odds of achieving LDL-C 
< 2.6 mmol/L was 4.8 in favor of EZ/Simva compared with Simva 40 mg (p < 
0.001), regardless of baseline LDL-C level. EZ/Simva is an effective therapeutic 
option for patients who have not achieved recommended LDL-C treatment targets 
with simvastatin 20 mg monotherapy. 
 
¾ G. Avellone, et al94., conducted a 1-year open-label study to test the efficacy and 
tolerability of Atorvastatin titrated to the target, in proven FH patients and to 
evaluate certain inflammatory parameters. One hundred and two FH patients (44 
men and 58 women; mean age 58.7+/-3.6 years) were included in the study. After 
evaluation using the B-mode duplex scanning system of extracranial carotid 
arteries, the patients were divided into two groups: Group 1 (15 men, 25 women) 
with carotid plaques or intima-media thickness (IMT) greater than 0.95 mm and 
Group 2 (30 men, 32 women) without carotid plaques or IMT less than 0.95 mm. 
After a 6-week hypolipemic diet phase all the patients were treated 
with atorvastatin titrated to achieve a low density lipoprotein (LDL-C) <100 
mg/dL. Patients with carotid lesions were also submitted to an oral fixed dose of 
aspirin 100 mg/day. In FH patients, 1-year atorvastatin treatment titrated to the 
target (LDL-C <100 mg/dL) was well tolerated and improved serum lipid levels 
and inflammatory parameters. 
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¾ Jones P. H, et al95., examined prospectively the effects of rosuvastatin, atorvastatin, 
simvastatin, and pravastatin across dose ranges on non-HDL-C, apo B, apo A-I, and 
total cholesterol (TC):HDL-C, low-density lipoprotein cholesterol (LDL-C):HDL-
C, non-HDL-C:HDL-C, and apoB:apoA-I ratios in patients with 
hypercholesterolemia (LDL-C > or =160 mg/dL and <250 mg/dL and triglycerides 
<400 mg/dL) in the Statin Therapies for Elevated Lipid Levels compared Across 
doses to Rosuvastatin (STELLAR) trial. Rosuvastatin 10 to 40 mg was more 
efficacious in improving the lipid profile of patients with hypercholesterolemia than 
milligram-equivalent doses of atorvastatin and milligram-equivalent or higher doses 
of simvastatin and pravastatin. 
 
¾ Roxanne A. Rodney, et al96., examined the efficacy and safety of ezetimibe (EZE) 
co administered with simvastatin (SIMVA) in a large cohort of African Americans 
with primary hypercholesterolemia. Eligible patients were randomized to SIMVA 
20 mg co administered with either EZE 10 mg (n = 124) or placebo (n = 123) for 
12 weeks. At study endpoint, EZE/SIMVA 10/20 mg resulted in a significant mean 
percent reduction in LDL cholesterol from baseline of 45.6% compared with 
28.3% for SIMVA 20 mg alone (p < or = 0.01). There were significantly greater 
mean reductions in total cholesterol (33% vs. 21%), triglycerides (median 22% vs. 
15%), nonhigh-density-lipoprotein (non-HDL) cholesterol (42% vs. 26%), and 
apolipoprotein B (38% vs. 25%) with EZE/SIMVA 10/20 mg compared with 
SIMVA 20 mg alone, respectively (p < or = 0.01). Co administration of 
EZE/SIMVA 10/20 mg demonstrated a safety profile similar to that of SIMVA 20 
mg. In conclusion, EZE/SIMVA 10/20 mg provided significantly greater 
improvement in atherogenic lipid profiles and was well tolerated compared with 
SIMVA 20-mg monotherapy in a large cohort of African Americans with primary 
hypercholesterolemia. 
 
¾ William Insull Jr, et al97., compared the effects of combination niacin extended-
release + simvastatin (NER/S) versus atorvastatin alone on apolipoproteins and 
lipid fractions in a post hoc analysis from SUPREME, a study which compared the 
lipid effects of niacin extended-release + simvastatin and atorvastatin in patients 
with hyperlipidemia or mixed dyslipidemia. NER/S treatment significantly 
improved apo A-I levels and the apo B:A-I ratio, significantly lowered the number 
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of atherogenic LDL particles and VLDL and chylomicron particles, and increased 
the mean size of LDL and VLDL particles, compared with atorvastatin. 
 
¾ F. van Nooten, et al98., aimed to assess the cost-effectiveness 
of ezetimibe plus simvastatin (E/S) versus atorvastatin or simvastatin monotherapy 
as second-line treatment of primary hypercholesterolemia from the Dutch 
healthcare perspective. The analysis showed the cost-effectiveness of E/S versus 
atorvastatin 20 mg or simvastatin 40 mg (EASEGO scenario) at a threshold of 
<euro>30,000/QALY and vs atorvastatin 40 mg was dominant (Dutch 
guidelines).Thus, E/S seems a valuable cost-effective second-line treatment option 
for patients not attaining lipid treatment goals. 
 
¾ Yun-Kyeong Cho, et al99., compared the effect of ezetimibe/simvastatin 10/20 mg 
and atorvastatin 20 mg on achieving a target LDL-C goal in very high risk patients. 
Baseline clinical and laboratory data were similar between the two groups. 
Achieving a target LDL-C goal was observed in 41.7% of Group 1 and 44.7% of 
Group 2 at 6 weeks (p=0.82). Changes in other lipid profiles were not significantly 
different but the tolerability of the two groups was similar. 
Ezetimibe/simvastatin 10/20 mg and atorvastatin 20 mg showed similar effects in 
achieving target LDL-C levels in patients with very high risk. 
 
¾ Tatjana Abel, et al100., determined the efficacy and safety of ezetimibe/ 
simvastatin 10/20mg combination therapy on patients with type 2 diabetes and 
nonalcoholic fatty liver disease. Six months of ezetimibe/ 
simvastatin administration reduced significantly the serum levels of ALT (63.78+/-
5.12 vs 32.57+/-3.92 U/L; p < 0.0001), AST (50.79+/-3.66 vs 23.68+/-3.42 U/L; p 
< 0.0001), cholesterol (6.26+/-0.46 vs 4.02+/-0.31 mmol/L; p < 0.0001) and LDL-
cholesterol (4.24+/-0.37 vs 2.22+/-0,1 mmol/L; p < 0.0001). Combination therapy 
reduced significantly serum triglyceride level (2.62+0.48 vs 1.33+0.20 mmol/L;                    
p < 0.0001) and increased the level of HDL-cholesterol (1.02+/-0.12 vs                    
1.18+ /-0.07 mmol/L; p < 0.0001). These findings indicate that ezetimibe/ 
simvastatin combination therapy is safe and effective in patients with type 2 
diabetes and nonalcoholic fatty liver disease. 
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¾ Kazuo Nakamura, et al101., conducted a study to compare the effects of 
atorvastatin plus aspirin combined therapy on inflammatory responses, endothelial 
cell function, and blood coagulation system in patients undergoing coronary artery 
bypass grafting (CABG) to aspirin monotherapy. The patients were randomized 
into atorvastatin plus aspirin combined therapy group and aspirin monotherapy 
group. Reduced total cholesterol in the combined therapy group was found in a 
short term of medication for 14 days. On postoperative day (POD)-14, inhibitory 
effects of the combined therapy on whole blood aggregation as well as platelet 
activation assessed by flow cytometry were stronger than those of the 
monotherapy. In conclusion, atorvastatin and aspirin combined therapy may bring 
beneficial effects to the patient after CABG. 
 
¾ Nicola Abate, et al102., compared the effects of ezetimibe/simvastatin (E/S) 
combination therapy, atorvastatin, and rosuvastatin in patients with DM, MS 
without DM, or neither disease. Treatments were compared by pooling across all 
doses for effects on low-density lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C), total cholesterol (TC), non–HDL-C, 
apolipoprotein B (ApoB), LDL-C:HDL-C, TC:HDL-C, and LDL-C goal 
attainment. In conclusion, E/S generally provided greater efficacy than either 
atorvastatin or rosuvastatin that was consistent across the subgroups of patients 
with DM, MS. 
 
¾ Joanna M. Young, et al103., evaluated the effect of coenzyme Q10 
supplementation on statin tolerance and myalgia in patients with previous statin 
related myalgia. Forty-four patients were randomized to coenzyme Q10 (200 
mg/day) or placebo for 12 weeks in combination with upward dose titration of 
simvastatin from 10 mg/day, doubling every 4 weeks if tolerated to a maximum of 
40 mg/day. Patients experiencing significant myalgia reduced their statin dose or 
discontinued treatment. Myalgia was assessed using a visual analogue scale. In 
conclusion, coenzyme Q10 supplementation did not improve statin tolerance or 
myalgia, although further studies are warranted. 
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¾ Sophie L. Rogers, et al104., conducted meta-analyses to assess the relative potency 
of atorvastatin and simvastatin across all possible dose combinations in terms of 
changes in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), 
triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C). Seventeen 
published trials and 1 unpublished study were included in the meta-analyses. It was 
found that atorvastatin was 2 to 4 times as potent as simvastatin in reducing TC, 
LDL-C, and TG, indicating that the dose equivalence of atorvastatin and 
simvastatin lay between 1: 2 and 1:4. In contrast, simvastatin was more effective 
than atorvastatin in increasing HDL-C, but without any indication of a point of 
dose equivalence. 
 
¾ Matthew A. Silva, et al105., conducted a meta-analysis study intended to 
synthesize the collective AE data observed in prospective randomized clinical trials 
to facilitate clinical interpretation. The MEDLINE/EMBASE and the Cochrane 
Collaboration databases were reviewed for prospective randomized primary and 
secondary prevention trials of statin monotherapy. Nonrandomized uncontrolled 
studies and those missing AE data were excluded. Statin therapy was associated 
with greater odds of AEs compared with placebo but with substantial clinical 
benefit. Similar rates of serious AEs were observed between statin and placebo. 
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AIM AND OBJECTIVES 
 
 
AIM: 
 
The aim of the study is a “comparative evaluation of the efficacy and side effect 
profile of Simvastatin versus Atorvastatin in Dyslipidemic Patients”. 
 
 
OBJECTIVES:  
 
¾ To assess the lipid profile of patients before and after drug administration. 
 
¾ To study the association of lipid profile and various demographic, clinical and 
personal habits( like age, gender, hypertension, diabetes mellitus, coronary artery 
disease, alcoholic, smoking and family history) in patients receiving Simvastatin 
and Atorvastatin. 
 
¾ To study the side effects if any, associated with drug intake in the above groups. 
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PLAN OF WORK 
 
 
The Proposed plan of the work is to compare the efficacy and side effect profile of 
Simvastatin versus Atorvastatin in Dyslipidemic Patients. 
 
 
 Collection of Dyslipidemic Patients. 
 
 Documentation of case History to find out the number of patients who has elevated 
levels of Total Cholesterol, Triglycerides, Low density Lipoprotein, and decreased 
levels of High Density Lipoprotein. 
 
 
 Assess the side effect profile of each patient during the study. 
 
 Analyze the collected Data. 
 
 
 Interpreting the data into statistical inference using statistical tools. 
 
 Submission of Results. 
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OBSERVATIONS AND RESULTS 
 
 
COMPARISON OF A20 WITH A40 
 
 
1. Comparison of Age between A20 and A40 
 
Table No: 7 Age Distribution 
 
Drug Mean Std. Deviation P value 
A20 
(Atorvastatin 20) 
55.03 10.220 
0.769 
A40 
(Atorvastatin 40) 
55.83 10.751 
 
 
When chi square test was done, p value was 0.769. So, there was no statistically 
significant difference between age distribution and the two study groups and the graphical 
representation is shown in Fig No: 2 
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2. Comparison of Sex Distribution between A20 and A40  
 
 
Table No: 8 Sex Distribution 
 
When Pearson chi square test was done, p value was 0.222. So, there was no 
statistically significant difference between sex and the two study groups and the graphical 
representation is shown in Fig No: 3 
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Sex Distribution
16.7
30.0
83.3
70.0
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
A20 A40
Pe
rc
en
t 
(%
)
Females
Males
 
 
 
 
 
 
Sex Distribution 
Drug 
p value A20 
(Atorvastatin 20)
A40 
(Atorvastatin 40) 
Female 
No: of patients 5 9 
0.222 
Percentage of patients 16.7% 30.0% 
Male 
No: of patients 25 21 
Percentage of patients 83.3% 70.0% 
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3. Comparison of Smoking  between A20 and A40 
 
 
 
Table No: 9 Smoking Status 
 
 
Smoking 
Drug 
A20 
(Atorvastatin 20) 
A40 
(Atorvastatin 40) 
Current-Smoker No: of patients 6 10 
Percentage of patients 20.0% 33.3% 
Ex-Smoker No: of patients 3 2 
Percentage of patients 10.0% 6.7% 
Non Smoker No: of patients 21 18 
Percentage of patients 70.0% 60.0% 
 
 
Statistical analysis using Fisher's Exact Test shows that p value is 1.000. Hence 
statistically it is not significant and the graphical representation is shown in Fig No: 4 
 
 
 
Fig No: 4  
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4. Comparison of Alcoholics between A20 and A40 
 
 
Table No: 10 Alcoholics 
 
 
Alcoholic 
Drug 
A20 
(Atorvastatin 20) 
A40 
(Atorvastatin 40) 
Present 
 
No: of patients 2 7 
Percentage of patients 6.7% 23.3% 
Absent No: of patients 28 23 
Percentage of patients 93.3% 76.7% 
 
 
Statistical analysis using Fisher's Exact Test shows that p value is 0.145. Hence 
statistically it is not significant and the graphical representation is shown in Fig No: 5 
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5. Comparison of Diabetes between A20 and A40 
 
 
Table No: 11 Diabetes Mellitus 
 
 
 
Statistical analysis using Fisher's Exact Test shows that p value is 1.000. Hence 
statistically it is not significant and the graphical representation is shown in Fig No: 6  
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Diabetics 
Drug 
A20 
(Atorvastatin 20) 
A40 
(Atorvastatin 40) 
On Insulin No: of patients 1 2 
Percentage of patients 3.3% 6.7% 
On Drugs No: of patients 16 17 
Percentage of patients 53.3% 56.7% 
Non Diabetic No: of patients 13 11 
Percentage of patients 43.4% 36.6% 
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6.  Comparison of Hypertension between A20 and A40 
 
 
Table No: 12 Hypertension 
 
 
Hypertension 
Drug 
A20 
(Atorvastatin 20) 
A40 
(Atorvastatin 40) 
Hypertensive No: of patients 18 14 
Percentage of patients 60.0% 46.7% 
Normotensive No: of patients 12 16 
Percentage of patients 40.0% 53.3% 
 
 
Statistical analysis using Pearson Chi-Square shows that p value is 0.301. Hence 
statistically it is not significant and the graphical representation is shown in Fig No: 7 
 
 
Fig No: 7 
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7. Comparison of Family History between A20 and A40 
 
 
 
Table No: 13 Family History 
 
Family History 
Drug 
A20 
(Atorvastatin 20) 
A40 
(Atorvastatin 40)
Present 
No: of patients 3 2 
Percentage of patients 10.0% 6.7% 
Absent 
No: of patients 27 28 
Percentage of patients 90.0% 93.3% 
 
 
Statistical analysis using Fisher's Exact Test shows that p value is 1.000. Hence 
statistically it is not significant and the graphical representation is shown in Figure. 8 
 
 
Fig No: 8 
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8. Comparison of Cardiovascular events between A20 and A40 
 
 
 
Table No: 14 Cardiovascular events 
 
CAD 
Drug 
A20 
(Atorvastatin 20) 
A40 
(Atorvastatin 40) 
Present 
No: of patients 25 26 
Percentage of patients 83.3% 86.7% 
Absent 
No: of patients 5 4 
Percentage of patients 16.7% 13.3% 
 
 
Statistical analysis using Fisher's Exact Test shows that p value is 1.000. Hence 
statistically it is not significant and the graphical representation is shown in Fig No: 9 
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9. Comparison of Total Cholesterol between A20 and A40 
 
 
 
Table No: 15 Total Cholesterol 
 
Drug Visit 1 Visit 2 Visit 3 p value 
A20 
(Atorvastatin 20) 
Mean 264.00 206.57 182.47  
 
 
<0.05 
Std. Deviation 31.414 29.600 22.332 
A40 
(Atorvastatin 40) 
Mean 275.10 180.07 139.90 
Std. Deviation 27.353 30.674 19.090 
 
When chi square test was done, p value was <0.05. So, the comparison of total 
cholesterol was found to be statistically significant and the graphical representation is 
shown in Fig No: 10 
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10. Comparison of Triglycerides between A20 and A40 
 
 
Table No: 16 Triglycerides 
 
Drug Visit 1 Visit 2 Visit 3 
A20 
(Atorvastatin 20) 
Mean 174.97 136.63 120.87 
Std. Deviation 29.188 22.474 19.722 
A40 
(Atorvastatin 40) 
Mean 201.33 139.43 106.77 
Std. Deviation 32.436 34.345 21.580 
p value <0.05 
 
 
When chi square test was done, p value was <0.05. So, the comparison of 
triglycerides was found to be statistically significant and the graphical representation is 
shown in Fig No: 11 
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11.  Comparison of HDL between A20 and A40 
 
  
Table No: 17 HDL 
 
 
When chi square test was done, p value was <0.05. So, the comparison of HDL 
with two study groups was found to be statistically significant and the graphical 
representation is shown in Fig No: 12 
 
 
Fig No: 12 
 
HDL cholesterol
34.8 36.7 36.933.2 34.0 34.0
0.0
10.0
20.0
30.0
40.0
50.0
60.0
Visit 1 Visit 2 Visit 3
H
D
L 
ch
ol
es
te
ro
l (
m
g/
dl
)
A20
A40
 
 
 
 
Drug Visit 1 Visit 2 Visit 3 
A20 
(Atorvastatin 20) 
Mean 34.80 36.73 36.93 
Std. Deviation 3.326 3.028 3.016 
A40 
(Atorvastatin 40) 
Mean 33.17 34.03 34.03 
Std. Deviation 3.573 3.605 5.875 
p value <0.05 
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12. Comparison of VLDL between A20 and A40 
 
 
Table No: 18 VLDL 
 
 
When chi square test was done, p value was <0.05. So, the comparison of VLDL 
with the two study groups was found to be statistically significant and the graphical 
representation is shown in Fig No: 13 
 
 
Fig No: 13 
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Drug Visit 1 Visit 2 Visit 3 
A20 
(Atorvastatin 20) 
Mean 35.13 27.27 24.07 
Std. Deviation 6.191 4.608 3.982 
A40 
(Atorvastatin 40) 
Mean 40.10 27.87 21.27 
Std. Deviation 6.424 6.827 4.266 
p value <0.05 
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13. Comparison of LDL between A20 and A40 
 
 
 
Table No: 19 LDL 
 
 
 
When chi square test was done, p value was <0.05. So, the comparison of LDL 
with the two study groups was found to be statistically significant and the graphical 
representation is shown in Fig No: 14 
 
Fig No: 14 
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Drug Visit 1 Visit 2 Visit 3 
A20 
(Atorvastatin 20) 
Mean 194.17 142.90 121.50 
Std. Deviation 30.744 28.521 22.218 
A40 
(Atorvastatin 40) 
Mean 202.47 117.83 84.67 
Std. Deviation 27.645 32.748 19.759 
p value <0.05 
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14. Comparison of Side effects between A20 and A40 
 
 
Table No: 20 Side effects 
 
Side effects 
Drug 
A20 
(Atorvastatin 20) 
A40 
(Atorvastatin 40)
General 
Weakness 
No: of patients 3 13 
Percentage of patients 10.0% 43.3% 
Myalgia 
No: of patients 1 8 
Percentage of patients 3.3% 26.7% 
LFT slightly 
elevated 
No: of patients 0 2 
Percentage of patients 0 6.7% 
 
 
Statistical analysis using Pearson Chi-Square test shows that p value was <0.05. Hence 
statistically it is significant and the graphical representation is shown in Fig No: 15  
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COMPARISON OF A20 WITH S40 
 
 
1. Comparison of Age between A20 and S40 
 
 
Table No: 21 Age Distribution 
 
Drug Mean Std. Deviation p value 
A20 
(Atorvastatin 20) 
55.03 10.220 
0.980 
S40 
(Simvastatin40) 
55.10 10.287 
 
 
When chi square test was done, p value was 0.980. So, there was no statistically 
significant difference between age distribution and the two study groups and the graphical 
representation is shown in Fig No: 16 
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Mean Age
55.8 55.1
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
A40 S40
M
ea
n 
ag
e 
(y
ea
rs
)
Series1
 
 
                                                                                       Observations & Results                         
 
Department of Pharmacy Practice                     66 
 
 
 
2. Comparison of Sex Distribution between A20 and S40 
 
 
Table No: 22 Sex Distribution 
 
 
 
When Pearson Chi-Square test was done, p value was 1.000. So, there was no 
statistically significant difference between Sex Distribution and the two study groups and 
the graphical representation is shown in Fig No: 17 
 
 
Fig No: 17  
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Sex Distribution 
Drug 
p value A20 
(Atorvastatin 20)
S40 
(Simvastatin 40) 
Female 
No: of patients 5 5 
1.000 
Percentage of patients 16.7% 16.7% 
Male 
No: of patients 25 25 
Percentage of patients 83.3% 83.3% 
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3. Comparison of Smoking between A20 and S40 
 
 
 
Table No: 23 Smoking status 
 
Smoking 
Drug 
A20 
(Atorvastatin 20) 
S40 
(Simvastatin 40) 
Current-Smoker No: of patients 6 5 
Percentage of patients 20.0% 16.7% 
Ex-Smoker No: of patients 3 0 
Percentage of patients 10.0% .0% 
Non Smoker No: of patients 21 25 
Percentage of patients 70.0% 83.3% 
 
 
Statistical analysis using Fisher's Exact Test shows that p value is 1.000. Hence 
statistically it is not significant and the graphical representation is shown in Fig No: 18 
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4. Comparison of Alcoholics between A20 and S40 
 
 
Table No: 24 Alcoholics 
 
 
Alcoholic 
Drug 
A20 
(Atorvastatin 20)
S40  
(Simvastatin 40) 
Present No: of patients 2 6 
Percentage of patients 6.7% 20.0% 
Absent No: of patients 28 24 
Percentage of patients 93.3% 80.0% 
 
 
 
Statistical analysis using Fisher's Exact Test shows that p value is 0.254. Hence 
statistically it is not significant and the graphical representation is shown in Fig No: 19 
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5. Comparison of Diabetes between A20 and S40 
 
Table No: 25 Diabetes 
 
 
 
Statistical analysis using Pearson Chi-Square shows that p value is 1.000. Hence 
statistically it is not significant and the graphical representation is shown in Fig No: 20 
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Diabetics 
Drug 
A20 
(Atorvastatin 20) 
S40 
(Simvastatin 40) 
On Insulin No: of patients 1 3 
Percentage of patients 3.3% 10.0% 
On Drugs No: of patients 16 16 
Percentage of patients 53.3% 53.3% 
Non Diabetic No: of patients 13 11 
Percentage of patients 43.4% 36.7% 
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6. Comparison of Hypertension between A20 and S40 
 
Table No: 26 Hypertension 
 
 
Hypertension 
Drug 
A20 
(Atorvastatin 20)
S40  
(Simvastatin 40) 
Hypertensive No: of patients 18 24 
Percentage of patients 60.0% 80.0% 
Normotensive No: of patients 12 6 
Percentage of patients 40.0% 20.0% 
 
 
Statistical analysis using Pearson Chi-Square shows that p value is 0.091. Hence 
statistically it is not significant and the graphical representation is shown in Fig No: 21 
 
 
Fig No: 21  
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7. Comparison of Family History between A20 and S40 
 
Table No: 27 Family History 
 
 
Family History 
Drug 
A20 
(Atorvastatin 20)
S40  
(Simvastatin 40) 
Present No: of patients 3 8 
Percentage of patients 10.0% 26.7% 
Absent No: of patients 27 22 
Percentage of patients 90.0% 73.3% 
 
 
Statistical analysis using Fisher's Exact Test shows that p value is 0.095. Hence 
statistically it is not significant and the graphical representation is shown in Fig No: 22 
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8. Comparison of Cardiovascular events between A20 and S40 
 
Table No: 28 Cardiovascular events 
 
 
CAD 
Drug 
A20 
(Atorvastatin 20) 
S40 
(Simvastatin 40) 
Present No: of patients 25 28 
Percentage of patients 83.3% 93.3% 
Absent No: of patients 5 2 
Percentage of patients 16.7% 6.7% 
 
 
Statistical analysis using Fisher's Exact Test shows that p value is 0.424. Hence 
statistically it is not significant and the graphical representation is shown in Fig No: 23 
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9. Comparison of Total Cholesterol between A20 and S40 
 
 
 
Table No: 29 Total Cholesterol 
 
Drug Visit 1 Visit 2 Visit 3 
A20 
(Atorvastatin 20) 
Mean 264.00 206.57 182.47 
Std. Deviation 31.414 29.600 22.332 
S40 
(Simvastatin40) 
Mean 279.80 138.10 109.27 
Std. Deviation 23.209 26.747 14.215 
p value <0.05 
 
When chi square test was done, p value was <0.05. So, the comparison of total 
cholesterol was found to be statistically significant and the graphical representation is 
shown in Fig No: 24 
 
Fig No: 24  
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10. Comparison of Triglycerides between A20 and S40 
 
 
Table No: 30 Triglycerides 
 
Drug Visit 1 Visit 2 Visit 3 p value 
A20 
(Atorvastatin 20) 
Mean 174.97 136.63 120.87 
<0.05 
Std. Deviation 29.188 22.474 19.722 
S40 
(Simvastatin40) 
Mean 217.33 115.07 94.73 
Std. Deviation 41.501 25.557 16.148 
 
 
When chi square test was done, p value was <0.05. So, the comparison of 
triglycerides was found to be statistically significant and the graphical representation is 
shown in Fig No: 25 
 
 
Fig No: 25 
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11. Comparison of HDL between A20 and S40 
 
 
 
Table No: 31 HDL 
 
Drug Visit 1 Visit 2 Visit 3 
A20 
(Atorvastatin 20) 
Mean 34.80 36.73 36.93 
Std. Deviation 3.326 3.028 3.016 
S40 
(Simvastatin40) 
Mean 32.83 36.63 37.10 
Std. Deviation 3.384 4.238 3.845 
p value <0.05 
 
 
When chi square test was done, p value was <0.05. So, the comparison of HDL 
with two study groups was found to be statistically significant and the graphical 
representation is shown in Fig No: 26 
 
 
Fig No: 26 
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12. Comparison of VLDL between A20 and S40 
 
 
Table No: 32 VLDL 
 
Drug Visit 1 Visit 2 Visit 3 
A20 
(Atorvastatin 20) 
Mean 35.13 27.27 24.07 
Std. Deviation 6.191 4.608 3.982 
S40 
(Simvastatin40) 
Mean 43.77 23.20 18.47 
Std. Deviation 9.265 5.235 3.350 
p value <0.05 
 
 
When chi square test was done, p value was <0.05. So, the comparison of VLDL 
with the two study groups was found to be statistically significant and the graphical 
representation is shown in Fig No: 27 
 
 
Fig No: 27 
 
Mean VLDL
35.1
27.3
24.1
43.8
23.2
18.5
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
45.0
50.0
Visit 1 Visit 2 Visit 3
M
ea
n 
V
LD
L 
(m
g/
dl
)
A20
S40
 
 
 
 
 
                                                                                       Observations & Results                         
 
Department of Pharmacy Practice                     77 
 
 
 
13. Comparison of LDL between A20 and S40 
 
 
Table No: 33 LDL 
 
Drug Visit 1 Visit 2 Visit 3 
A20 
(Atorvastatin 20) 
Mean 194.17 142.90 121.50 
Std. Deviation 30.744 28.521 22.218 
S40 
(Simvastatin40) 
Mean 202.43 78.10 53.30 
Std. Deviation 24.060 24.493 12.123 
p value <0.05 
 
 
 
When chi square test was done, p value was <0.05. So, the comparison of LDL 
with the two study groups was found to be statistically significant and the graphical 
representation is shown in Fig No: 28 
 
 
Fig No: 28 
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14. Comparison of Side effects between A20 and S40 
 
  
Table No: 34 Side effects 
 
 
Side effects 
Drug 
A20 
(Atorvastatin 20) 
S40 
(Simvastatin 40) 
General 
Weakness 
No: of patients 3 21 
Percentage of patients 10.0% 70.0% 
Myalgia 
No: of patients 1 10 
Percentage of patients 3.3% 33.3% 
LFT slightly 
elevated 
No: of patients 0 2 
Percentage of patients 0 6.7% 
Pedal Odema 
No: of patients 0 2 
Percentage of patients 0 6.7% 
 
Statistical analysis using Pearson Chi-Square test shows that p value is <0.05. 
Hence statistically it is significant and the graphical representation is shown in Fig No: 29 
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COMPARISON OF A40 WITH S40 
 
 
1. Comparison of Age Distribution between A40 and S40 
 
 
 
Table No: 35   Age Distribution 
 
Drug Mean Std. Deviation 
 
p value 
A40 
(Atorvastatin 40) 
55.83 10.751 
0.788 
S40 
(Simvastatin 40) 
55.10 10.287 
 
 
When chi square test was done, p value was 0.788. So, there was no statistically 
significant difference between age distribution and the two study groups and the graphical 
representation is shown in Fig No: 30 
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2. Comparison of Sex Distribution between A40 and S40 
 
 
Table No: 36 Sex Distribution 
 
 
When Pearson Chi-Square test was done, p value was 0.222. So, there was no 
statistically significant difference between Sex Distribution and the two study groups and 
the graphical representation is shown in Fig No: 31 
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Sex 
Drug 
 
p value 
A40 
(Atorvastatin 40) 
S40 
(Simvastatin 40) 
Female 
No: of patients 9 5 
0.222 
Percentage of patients 30.0% 16.7% 
Male 
No: of patients 21 25 
Percentage of patients 70.0% 83.3% 
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3. Comparison of Smoking between A40 and S40 
 
 
Table No: 37 Smoking Status 
 
 
Smoking 
Drug 
  A40 
(Atorvastatin 40) 
S40  
(Simvastatin 40) 
Current-Smoker No: of patients 10 5 
Percentage of patients 33.3% 16.7% 
Ex-Smoker No: of patients 2 0 
Percentage of patients 6.7% .0% 
Non Smoker No: of patients 18 25 
Percentage of patients 60.0% 83.3% 
 
 
Statistical analysis using Fisher's Exact Test shows that p value is 0.492. Hence 
statistically it is not significant and the graphical representation is shown in Fig No: 32 
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4. Comparison of Alcoholics between A40 and S40 
 
 
Table No: 38 Alcoholics 
 
 
Alcoholic 
Drug 
  A40 
(Atorvastatin 40)
S40  
(Simvastatin 40) 
Present No: of patients 7 6 
Percentage of patients 23.3% 20.0% 
Absent No: of patients 23 24 
Percentage of patients 76.7% 80.0% 
 
 
Statistical analysis using Pearson Chi-Square shows that p value is 0.754. Hence 
statistically it is not significant and the graphical representation is shown in Fig No: 33. 
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5. Comparison of Diabetes between A40 and S40 
 
 
Table No: 39 Diabetes 
 
Statistical analysis using Pearson Chi-Square shows that p value is 0.795. Hence 
statistically it is not significant and the graphical representation is shown in Fig No: 34. 
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Diabetics 
Drug 
A40 
(Atorvastatin 40)
S40 
(Simvastatin 40) 
On Insulin 
No: of patients 2 3 
Percentage of patients 6.7% 10.0% 
On Drugs 
No: of patients 17 16 
Percentage of patients 56.7% 53.3% 
Non Diabetic 
No: of patients 11 11 
Percentage of patients 36.6% 36.7% 
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6. Comparison of Hypertension between A40 and S40 
 
 
Table No: 40 Hypertension 
 
 
Hypertension 
Drug 
A40 
(Atorvastatin 40) 
S40 
(Simvastatin 40) 
Hypertensive 
No: of patients 14 24 
Percentage of patients 46.7% 80.0% 
Normotensive 
No: of patients 16 6 
Percentage of patients 53.3% 20.0% 
 
 
Statistical analysis using Pearson Chi-Square shows that p value is 0.007. Hence 
statistically it is significant and the graphical representation is shown in Fig No: 35. 
 
 
Fig No: 35 
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7. Comparison of Family History between A40 and S40 
 
Table No: 41 Family History 
 
 
Family History 
Drug 
  A40 
(Atorvastatin 40)
S40  
(Simvastatin 40) 
Present No: of patients 2 8 
Percentage of patients 6.7% 26.7% 
Absent No: of patients 28 22 
Percentage of patients 93.3% 73.3% 
 
 
Statistical analysis using Pearson Chi-Square shows that p value is 0.038. Hence 
statistically it is significant and the graphical representation is shown in Fig No: 36. 
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8. Comparison of Cardiovascular events between A40 and S40 
 
 
 
Table No: 42 Cardiovascular events 
 
 
CAD 
Drug 
  A40 
(Atorvastatin 40) 
S40  
(Simvastatin 40) 
Present No: of patients 26 28 
Percentage of patients 86.7% 93.3% 
Absent No: of patients 4 2 
Percentage of patients 13.3% 6.7% 
 
 
 
Statistical analysis using Fisher's Exact Test shows that p value is 0.671. Hence 
statistically it is not significant and the graphical representation is shown in Fig No: 37 
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9. Comparison of Total Cholesterol between A40 and S40 
 
 
Table No: 43 Total Cholesterol 
 
Drug Visit 1 Visit 2 Visit 3 
A40 
(Atorvastatin 40) 
Mean 275.10 180.07 139.90 
Std. Deviation 27.353 30.674 19.090 
S40 
(Simvastatin 40) 
Mean 279.80 138.10 109.27 
Std. Deviation 23.209 26.747 14.215 
p value <0.05 
 
 
When chi square test was done, p value was <0.05. So, the comparison of total 
cholesterol was found to be statistically significant and the graphical representation is 
shown in Fig No: 38. 
 
 
Fig No: 38  
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10. Comparison of Triglycerides between A40 and S40 
 
 
Table No: 44 Triglycerides 
 
Drug Visit 1 Visit 2 Visit 3 
A40 
(Atorvastatin 40) 
Mean 201.33 139.43 106.77 
Std. Deviation 32.436 34.345 21.580 
S40 
(Simvastatin 40) 
Mean 217.33 115.07 94.73 
Std. Deviation 41.501 25.557 16.148 
p value <0.05 
 
 
When chi square test was done, p value was <0.05. So, the comparison of 
triglycerides was found to be statistically significant and the graphical representation is 
shown in Fig No: 39. 
 
 
 
Fig No: 39 
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11. Comparison of HDL between A40 and S40 
 
 
Table No: 45 HDL 
 
Drug Visit 1 Visit 2 Visit 3 
A40 
(Atorvastatin 40) 
Mean 33.17 34.03 34.03 
Std. Deviation 3.573 3.605 5.875 
S40 
(Simvastatin 40) 
Mean 32.83 36.63 37.10 
Std. Deviation 3.384 4.238 3.845 
p value <0.05 
 
 
When chi square test was done, p value was <0.05. So, the comparison of HDL 
with two study groups was found to be statistically significant and the graphical 
representation is shown in Fig No: 40. 
 
 
Fig No: 40 
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12. Comparison of VLDL between A40 and S40 
 
 
Table No: 46 VLDL 
 
Drug Visit 1 Visit 2 Visit 3 
A40 
(Atorvastatin 40) 
Mean 40.10 27.87 21.27 
Std. Deviation 6.424 6.827 4.266 
S40 
(Simvastatin 40) 
Mean 43.77 23.20 18.47 
Std. Deviation 9.265 5.235 3.350 
p value <0.05 
 
 
When chi square test was done, p value was <0.05. So, the comparison of VLDL 
with the two study groups was found to be statistically significant and the graphical 
representation is shown in Fig No: 41. 
 
Fig No: 41 
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13. Comparison of LDL between A40 and S40 
 
 
Table No: 47 LDL 
 
Drug Visit 1 Visit 2 Visit 3 
A40 
(Atorvastatin 40) 
Mean 202.47 117.83 84.67 
Std. Deviation 27.645 32.748 19.759 
S40 
(Simvastatin 40) 
Mean 202.43 78.10 53.30 
Std. Deviation 24.060 24.493 12.123 
p value <0.05 
 
 
When chi square test was done, p value was <0.05. So, the comparison of LDL 
with the two study groups was found to be statistically significant and the graphical 
representation is shown in Fig No: 42. 
 
Fig No: 42  
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14. Comparison of Side effects between A40 and S40 
 
Table No: 48 Side effects 
 
 
Side effects 
Drug 
A40 
(Atorvastatin 40) 
S40 
(Simvastatin 40) 
General 
Weakness 
No: of patients 13 21 
Percentage of patients 43.3% 70.0% 
Myalgia No: of patients 8 10 
Percentage of patients 26.7% 33.3% 
LFT slightly 
elevated 
No: of patients 2 2 
Percentage of patients 6.7% 6.7% 
Pedal Odema No: of patients 0 2 
Percentage of patients 0 6.7% 
         
 
Statistical analysis using Pearson Chi-Square shows that p value is 0.037. Hence 
statistically it is significant and the graphical representation is shown in Fig No: 43. 
 
 
Fig No: 43 
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COMPARATIVE EFFICACY 
 
Percentage Changes in Total Cholesterol 
 
 
Table No: 49   Percentage Changes in Total Cholesterol 
 
Drug 
Percentage Change 
TC12 
Percentage Change 
TC13 
A20 
(Atorvastatin 20) 
 
21.8372 
 
 
30.6483 
 
A40 
(Atorvastatin 40) 
 
34.4525 
 
 
49.0035 
 
S40 
(Simvastatin 40) 
 
50.5037 
 
 
60.7804 
 
 
The comparison of total cholesterol in Simvastatin and Atorvastatin patients were 
found to be statistically significant and the graphical representation is shown in Fig No: 
44.  It shows that Simvastatin 40 mg is better than Atorvastatin 40mg which is better than 
Atorvastatin 20mg in the reduction of total cholesterol. 
 
Fig No: 44 
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Percentage Changes in HDL 
 
 
Table No: 50   Percentage Changes in HDL 
 
Drug 
Percentage Change 
HDL12 
Percentage Change 
HDL13 
A20 
(Atorvastatin 20) 
 
5.8220 
 
 
6.5578 
 
A40 
(Atorvastatin 40) 
 
2.9446 
 
 
2.8513 
 
S40 
(Simvastatin 40) 
 
11.9324 
 
 
13.6489 
 
 
 
The comparison of HDL in Simvastatin and Atorvastatin patients were found to be 
statistically significant and the graphical representation is shown in Fig No: 45. It shows 
that Simvastatin 40 mg is better than Atorvastatin 20mg which is better than Atorvastatin 
40mg in the reduction of HDL. 
 
Fig No: 45 
 
Percent Increase in HDL
5.
82
2.
94
11
.9
3
6.56
2.85
13.65
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
A20 A40 S40
Pe
ce
nt
 (%
)
By 2nd visit
By 3rd visit
 
                                                                                       Observations & Results                         
 
Department of Pharmacy Practice                     95 
 
 
 
 
Percentage Changes in Triglycerides 
 
 
Table No: 51   Percentage Changes in Triglycerides 
 
Drug 
Percentage Change 
TG12 
Percentage Change 
TG13 
A20 
(Atorvastatin 20) 
 
21.3958 
 
 
30.1197 
 
A40 
(Atorvastatin 40) 
 
30.9766 
 
 
46.3713 
 
S40 
(Simvastatin 40) 
 
46.7485 
 
55.9384 
 
 
 
The comparison of Triglycerides in Simvastatin and Atorvastatin patients were 
found to be statistically significant and the graphical representation is shown in Fig No: 
46. It shows that Simvastatin 40 mg is better than Atorvastatin 40mg which is better than 
Atorvastatin 20mg in the reduction of Triglycerides. 
 
Fig No: 46 
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Percentage Changes in LDL 
 
 
Table No: 52   Percentage Changes in LDL 
 
 
Drug 
Percentage Change 
LDL12 
Percentage Change 
LDL13 
A20 
(Atorvastatin 20) 
 
26.6861 
 
 
37.1870 
 
A40 
(Atorvastatin 40) 
 
41.9303 
 
 
58.1757 
 
S40 
(Simvastatin 40) 
 
61.1929 
 
73.3689 
 
 
The comparison of LDL in Simvastatin and Atorvastatin patients were found to be 
statistically significant and the graphical representation is shown in Fig No: 47. It shows 
that Simvastatin 40 mg is better than Atorvastatin 40mg which is better than Atorvastatin 
20mg in the reduction of LDL. 
 
 
Fig No: 47 
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Percentage Changes in VLDL 
 
 
Table No: 53 Percentage Changes in VLDL 
 
Drug 
Percentage Change 
VLDL12 
Percentage Change 
VLDL13 
A20 
(Atorvastatin 20) 
 
21.7580 
 
 
30.5711 
 
A40 
(Atorvastatin 40) 
 
30.7205 
 
 
46.3703 
 
S40 
(Simvastatin 40) 
 
46.6156 
 
57.2205 
 
 
The comparison of VLDL in Simvastatin and Atorvastatin patients were found to 
be statistically significant and the graphical representation is shown in Fig No: 48. It 
shows that Simvastatin 40 mg is better than Atorvastatin 40mg which is better than 
Atorvastatin 20mg in the reduction of VLDL. 
 
 
Fig No: 48 
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 DISCUSSION 
 
The present study was designed to primarily compare efficacy and side effect 
profile of Simvastatin versus Atorvastatin at the doses prescribed in routine clinical 
practice. Due to the observational nature of this study, dose to dose comparisons between 
simvastatin and Atorvastatin relied mainly on the sample size available in each of the 
groups. Three comparisons are carried out in this study: 
 
¾ Atorvastatin 20mg is compared with Atorvastatin 40mg. 
¾ Atorvastatin 20mg is compared with Simvastatin 40mg. 
¾ Atorvastatin 40mg is compared with Simvastatin 40mg. 
 
This was a randomized controlled study, and there were some baseline differences 
between simvastatin and Atorvastatin treated patients. Patients were matched on relevant 
characteristics and co-morbidities before their data were abstracted. 
 
The findings of the present study provide valuable information in aiding decisions 
on therapeutic drug selection for patients with Dyslipidemia in actual clinical practice 
settings. Furthermore, diet and exercise could also influence the results of patient’s lipid 
levels. 
 
Age Distribution and Dyslipidemia  
 
The age differed in Atorvastatin 20, Atorvastatin 40 and Simvastatin 40 study 
groups as shown in Table No: 7, Table No: 21, Table No: 35. Thus there was no statistical 
significant difference between age and the study groups. 
 
Sex Distribution and Dyslipidemia 
 
The sex differed in Atorvastatin 20, Atorvastatin 40 and Simvastatin 40 study 
groups. Male patients were found to be higher when compared to female patients as shown 
in Table No: 8, Table No: 22, Table No: 36. Thus there was no statistical significant 
difference between sex and the study groups. 
 
                   
Discussion                         
 
Department of Pharmacy Practice    99 
 
Smoking and Dyslipidemia 
 
The smoking status differed in Atorvastatin 20, Atorvastatin 40 and Simvastatin 40 
study groups as shown in Table No: 9, Table No: 23, Table No: 37. It shows that there was 
no statistical significant difference between smoking and the study groups. 
 
Alcoholic and Dyslipidemia 
 
The alcoholics differed in Atorvastatin 20, Atorvastatin 40 and Simvastatin 40 
study groups as shown in Table No: 10, Table No: 24, Table No: 38. It shows that there 
was no statistical significant difference between alcoholism and the study groups. 
 
Dyslipidemia and Diabetes Mellitus 
 
Diabetes Mellitus is well a recognized risk factor for Dyslipidemia. In the present 
study, the diabetes alone was not an independent risk factor for the development of 
Dyslipidemia. There was no significant difference between diabetics and non diabetics. 
 
Dyslipidemia and Hypertension 
 
The comparison of dyslipidemia in Hypertensive patients did show any significant 
difference. 
 
CAD and Dyslipidemia 
 
The occurrence of CAD in patients who had taken Simvastatin 40mg is 93.3%, 
86.7% in Atorvastatin 40mg and 83.3% in Atorvastatin 20mg. 
 
Changes in Total Cholesterol 
 
The present study was found that in second visit Atorvastatin 20mg reduces the 
total cholesterol by 21.84%, while Atorvastatin 40mg reduces the total cholesterol by 
34.45%.  In Third visit, Atorvastatin 20mg reduces the total cholesterol by 30.65% while 
Atorvastatin 40mg reduces the total cholesterol by 49%. Thus Atorvastatin 40mg is better 
than Atorvastatin 20mg. 
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Also it was found that in second visit Atorvastatin 20mg reduces the total 
cholesterol by 21.84% while Simvastatin 40mg reduces the total cholesterol by 50.50%. In 
Third visit, Atorvastatin 20mg reduces the total cholesterol by 30.65% while Simvastatin 
40mg reduces the total cholesterol by 60.78%. Thus Simvastatin 40mg is better than 
Atorvastatin 20mg. 
 
Also it was found that in second visit Atorvastatin 40mg reduces the total 
cholesterol by 34.45%, while Simvastatin 40mg reduces the total cholesterol by 50.50%. 
In Third visit, Atorvastatin 40mg reduces the total cholesterol by 49%, while Simvastatin 
40mg reduces the total cholesterol by 60.78%. Thus Simvastatin 40mg is better than 
Atorvastatin 40mg. 
 
Changes in High Density Lipoprotein levels 
 
The present study was found that in second visit Atorvastatin 20mg increases the 
HDL by 5.82% while Atorvastatin 40mg increases the HDL by 2.94%. In Third visit, 
Atorvastatin 20mg increases the HDL by 6.56% while Atorvastatin 40mg increases the 
HDL by 2.85%. It shows that Atorvastatin 20mg is better than Atorvastatin 40mg. 
 
Also it was found in second visit, Atorvastatin 20mg increases the HDL by 5.82% 
while Simvastatin 40mg increases the HDL by 11.93%. In Third visit, Atorvastatin 20mg 
increases the HDL by 6.56% while Simvastatin 40mg increases the HDL by 13.65%. It 
shows that Simvastatin 40mg is better than Atorvastatin 20mg. 
 
Also it was found that that in second visit Atorvastatin 40mg increases the HDL by 
2.94% while Simvastatin 40mg increases the HDL by 11.93%. In Third visit, Atorvastatin 
40mg increases the HDL by 2.85% while Simvastatin 40mg increases the HDL by 
13.65%. It shows that Simvastatin 40mg is better than Atorvastatin 40 mg. 
 
 
 
 
                   
Discussion                         
 
Department of Pharmacy Practice    101 
 
Changes in Low Density Lipoprotein levels 
 
The present study was found that in second visit Atorvastatin 20mg reduces the 
LDL by 26.69% while Atorvastatin 40mg reduces the LDL by 41.93%.%. In Third visit, 
Atorvastatin 20mg reduces the LDL by 37.19% while Atorvastatin 40mg reduces the LDL 
by 58.18%. It shows that Atorvastatin 40mg is better than Atorvastatin 20mg. 
 
Also it was found that in second visit Atorvastatin 20mg reduces the low density 
lipoprotein by 26.69% while Simvastatin 40mg reduces the LDL by 61.19%. In Third 
visit, Atorvastatin 20mg reduces the LDL by 37.19% while Simvastatin 40mg reduces the 
LDL by 73.37%. It shows that Simvastatin 40mg is better than Atorvastatin 20mg. 
 
Also it was found that in second visit Atorvastatin 40mg reduces the LDL by 
41.93% while Simvastatin 40mg reduces the LDL by 61.19%. In Third visit, Atorvastatin 
40mg reduces the LDL by 58.18% while Simvastatin 40mg reduces the LDL by 73.37%. It 
shows that Simvastatin 40mg is better than Atorvastatin 40mg. 
 
Changes in Triglycerides levels 
 
The present study was found that in second visit Atorvastatin 20mg reduces the TG 
by 21.4% while Atorvastatin 40mg reduces the TG by 30.98%. In Third visit, Atorvastatin 
20mg reduces the TG by 30.12% while Atorvastatin 40mg reduces the TG by 46.37%. It 
shows that Atorvastatin 40mg is better than Atorvastatin 20mg.  
 
Also it was found that in second visit Atorvastatin 20mg reduces the triglycerides 
by 21.4% while Simvastatin 40mg reduces the TG by 46.75%. In Third visit, Atorvastatin 
20mg reduces the TG by 30.12% while Simvastatin 40mg reduces the TG by 55.94%. It 
shows that Simvastatin 40mg is better than Atorvastatin 20mg. 
 
Also it was found that in second visit Atorvastatin 40mg reduces the TG by 
30.98% while Simvastatin 40mg reduces the TG by 46.75%. In Third visit, Atorvastatin 
40mg reduces the TG by 46.37% while Simvastatin 40mg reduces the TG by 55.94%. It 
shows that Simvastatin 40mg is better than Atorvastatin 40mg. 
                   
Discussion                         
 
Department of Pharmacy Practice    102 
 
 
Changes in Very Low Density Lipoprotein levels 
 
The present study was found that in second visit, Atorvastatin 20mg reduces the 
VLDL by 21.76% while Atorvastatin 40mg reduces the VLDL by 30.72%. In Third visit, 
Atorvastatin 20mg reduces the VLDL by 30.57% while Atorvastatin 40mg reduces the 
VLDL by 46.37%. It shows that Atorvastatin 40mg is better than Atorvastatin 20mg. 
 
Also it was found that in second visit, Atorvastatin 20mg reduces the VLDL by 
21.76% while Simvastatin 40mg reduces the VLDL by 46.62%. In Third visit, 
Atorvastatin 20mg reduces the VLDL by 30.57% while Simvastatin 40mg reduces the 
VLDL by 57.22%. It shows that Simvastatin 40mg is better than Atorvastatin 20mg. 
 
Also it was found that in second visit Atorvastatin 40mg reduces the VLDL by 
30.72% while Simvastatin 40mg reduces the VLDL by 46.62%. In Third visit, 
Atorvastatin 40mg reduces the VLDL by 46.37% while Simvastatin 40mg reduces the 
VLDL by 57.22%. It shows that Simvastatin 40mg is better than Atorvastatin 40mg. 
 
Incidence of side effects 
 
In this study, the side effects observed in the patients are: 
¾ General Weakness 
¾ Myalgia 
¾ LFT Slightly Elevated 
¾ Pedal Odema 
 
In the present study, 70% of the patients who had taken Simvastatin 40mg showed 
General Weakness whereas in Atorvastatin 40mg study group, 43.5% of the patients 
showed General Weakness. In the Atorvastatin 20mg study group, only 10% of the 
patients showed General Weakness. 
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Also, 33.3% of the patients who had taken Simvastatin 40mg showed Myalgia, 
whereas in Atorvastatin 40mg study group, 26.7% of the patients showed Myalgia. In 
the Atorvastatin 20mg study group, only 3.3% of the patients showed Myalgia. 
 
Also, 6.7% of the patients who had taken Simvastatin 40mg and Atorvastatin 40mg 
showed Slight Elevation in LFT. 
 
Also, 6.7% of the patients who had taken Simvastatin 40mg showed Pedal Odema. 
 
 
Thus the present study showed that the incidence of side effects was more in 
Simvastatin 40mg when compared to Atorvastatin 40mg and it was very less in 
Atorvastatin 20mg. 
 
The results of the present study showed that Simvastatin 40mg produce sudden 
reductions in LDL-C, total cholesterol, Triglycerides, and an increase in HDL-C when 
compared to Atorvastatin 40mg but the incidence of side effects were more in Simvastatin 
40mg. 
 
Also it was showed that Atorvastatin 40mg produce sudden reductions in LDL-C, 
total cholesterol, Triglycerides when compared to Atorvastatin 20mg. But in increasing 
HDL-C, Atorvastatin 20mg is better when compared to Atorvastatin 40mg as shown in 
Table No: 50. 
 
              
 
                                                                                                    Conclusion 
 
Department of Pharmacy Practice                      104 
 
 
CONCLUSION 
 
 
Patients treated with Simvastatin 40mg had significantly greater reductions in total 
cholesterol, low density lipoprotein, triglycerides, very low density lipoprotein and an 
increase in high density lipoprotein. But due to the high incidence of side effects, 
Simvastatin 40mg is not recommended for a longer period. 
 
As the incidence of side effects of Atorvastatin 40mg is less when compared to 
Simvastatin 40mg, Atorvastatin 40mg is better than Simvastatin 40mg. 
 
From this study, I found that for the patients who had underwent PTCA, the 
doctors usually advice to take Atorvastatin 40mg for the sudden reduction of lipid levels 
especially Low Density Lipoprotein and the Doctors advise to take Atorvastatin 40mg for 
approximately one year along with the Lifestyle modifications. 
 
After the LDL-C reaches the desired margin (Approximately below 100mg/dl), the 
patients are advised to replace Atorvastatin 40mg with Atorvastatin 20mg. This is due to 
the fact that Atorvastatin 20mg increases HDL value than Atorvastatin 40mg. 
 
 
